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ABSTRACT 
This work tested the hypothesis that oxidation of methionine 388 in thrombomodulin is 
higher in cigarette smokers, and thus a likely contributor towards the hypercoagulable state in 
smokers. Thrombomodulin, a protein cofactor found on endothelial cell surfaces, regulates the 
activity of thrombin. Thrombin bound to thrombomodulin no longer converts fibrinogen to 
fibrin, but instead activates Protein C which, in turn, stops the coagulation cascade by 
inactivation of clotting factors. The oxidation of methionine 388 of thrombomodulin has been 
shown in vitro to dramatically decrease the anticoagulant cofactor activity of thrombomodulin. 
The blood of cigarette smokers is more prone to clot than that of non-smokers, a major factor in 
their premature deaths from cardiovascular disease. Cigarette smoke consists of many oxidizing 
species that impose oxidative stress on the body. These species include organic radicals and 
hydrogen peroxide, which can oxidize methionine. The fact that smokers are in a 
hypercoagulable state has been established, however the molecular origins of such a state have 
not been elucidated. Techniques were developed to isolate thrombomodulin cleared from the 
blood stream in urine, proteolytically digest it, and identify using mass spectrometry the peptide 
containing methionine 388 in both its oxidized and reduced forms.  In many cases the oxidized 
version of the peptide was below the limits of detection in non-smokers and the reduced version 
was not detected in smokers. The intensity of these peaks in the mass spectra do not allow 
calculation of absolute percentages of oxidation because of differences in proton affinity of the 
two forms, but there is a very statistically significant difference (P=0.002 by Mann-Whitney 
Rank Sum test) in the apparent median reduced to oxidized ratios of >2.043 for non-smokers and 
of <0.308 for smokers.  The much greater degree of oxidation of thrombomodulin methionine 
388 in smokers should be examined for its contribution to smoking morbidity and mortality. 
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CHAPTER 1: DOES THE OXIDATION OF METHIONINE 388 IN THROMBOMODULIN    
CONTRIBUTE TOWARDS THE HYPERCOAGUABLE STATE IN CIGARETTE 
SMOKERS? 
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General introduction 
Proteins are susceptible to oxidation and there are several consequences of that.  
Oxidation can lead to modification of side chain properties, dimerization of the protein, 
conformational changes, unfolding of the protein or loss of activity, cleavage of the protein 
backbone [1], effects on expression and gene regulation, and affect cell signaling [2]. Studies 
have shown higher levels of oxidized proteins are found with aging, oxidative stress, also with 
diabetes, atherosclerosis and neurodegenerative diseases [3-6].  Amino acids liable to oxidation 
[7, 8] are cysteine, methionine, tryptophan, phenylalanine, tyrosine, histidine, arginine, lysine, 
proline, and threonine.  Cysteine and methionine stand out as the two amino acids that are most 
easily oxidized [3]. Cysteine can easily be converted to disulfide and methionine to methionine 
sulfoxide.  
Aerobic organisms rely on oxygen for the production of ATP during oxidative 
phosphorylation. Oxygen is the ultimate electron acceptor during this biosynthesis, and water is 
one of the byproducts of this reaction. However, transfer of single electron to a molecule of 
oxygen results in production of superoxide anion, a highly reactive radical. The protonated 
superoxide radical can react with another molecule of superoxide anion, which produces 
hydrogen peroxide. Superoxide radical falls under a category of compounds called reactive 
oxygen species (ROS). Physiological levels of ROS are important for cellular functions like gene 
expressions, signal transduction, apoptosis and immune response [9]. However, high 
concentrations of ROS can damage biomolecules like DNA, lipids and proteins.  Superoxide 
dismutase, an enzyme present in all aerobic organisms, along with catalase, a heme protein, 
converts the superoxide radical and hydrogen peroxide into water and molecular oxygen and act 
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as just one of the defense mechanisms against oxidative damage.  However, oxidation of proteins 
still occurs, often at methionine. 
Methionine is a non polar amino acid; along with cysteine they are the only two amino 
acids that contain sulfur.  The sulfur atom exists as a thioether linkage in methionine.  In the 
presence of reactive oxygen species (ROS), methionine is converted to methionine sulfoxide. In 
contrast to methionine, methionine sulfoxide’s side chain is polar. The conversion of important 
methionine residues to sulfoxide within a protein, can lead alteration of structure and 
functionality [10]. The sulfoxide form of methionine can be converted back to methionine by 
naturally occurring methionine sulfoxide reductases (MSRs) [4, 11, 12].  It has been shown in 
Alzheimer’s disease [13, 14] and aging, the physiological concentrations of MSRs are low, and 
they are unable to reduce all sulfoxides.  This has led to speculation that oxidative stress and 
methionine oxidation contribute to the development of Alzheimer’s disease [15]. 
Why might oxidation of a protein lead to such far-reaching consequences as 
Alzheimer’s?  Proteins are ubiquitous in all biological processes, and they play crucial roles in 
them. They are associated with enzyme catalysis, immune system, nerve impulses, motion, 
mechanical support, transport and storage among other processes that occur within a living 
organism. The remarkable range of activities proteins perform arises from their ability to fold 
into unique three-dimensional structures. This allows them to interact with wide range of 
molecules. Some of the noteworthy features of the native protein are: Polypeptides can fold in 
such a fashion, that distant amino acid residues on the polypeptide chain can be close in 
proximity to each other. Globular proteins are compact; they exclude almost all water from the 
inner hydrophobic core. The native protein is stabilized in the tertiary state by the following 
types of interactions.  There are hydrophobic interactions, where hydrophobic side chains are 
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brought into close proximity to each other. Electrostatic interactions occur between the ionic 
groups. Hydrogen bonding, where hydrogen bonds are formed between the side chains and also 
between the polypeptide backbones. Covalent bonds, disulfide bonds formed between the 2 
cysteine residues. If any of these interactions are disrupted, it could alter the structure of the 
protein, and consequently alters the functionality of the protein, which could lead to 
complications, or worse lead to development of diseases. Sickle cell anemia demonstrates how a 
substitution of single amino acid can have drastic effect on the functionality of a protein. In 
sickle cell anemia, body produces a variant of hemoglobin, where sixth position of the β-globin 
gene codes for valine, instead of glutamic acid [16].  Could high levels of oxidation of a single 
side chain in the right protein have similarly profound consequences? 
Cardiovascular diseases are the number one cause of death in the United States. The 
American Heart Association estimates that one out of three Americans die of cardiovascular 
death, and 80,700,000 people in the United States have one or more forms of cardiovascular 
disease [17, 18]. National Health and Nutrition Examination Survey (NHANES) reports 7.2% of 
Americans to have some type of cardiovascular diseases. This number comprised of 3.2% with 
coronary heart disease, 2.7% with stroke, and 2.0% with congestive heart failure, also many 
patients reported more than 1 condition [19].  
Annually 437,900 people are killed by diseases caused by smoking, and 35% of those 
deaths are cardiovascular related [20]. Cigarette smoke is the major cause of pulmonary 
emphysema [21], bronchitis, myocardial infarction, and stroke as well as lung cancer. Four 
million people die every year from tobacco smoking related diseases worldwide. It has been 
estimated that 2 billion people use tobacco products [22].  Approximately 64.5 million people in 
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the USA are active smokers, between 1995-1999 the estimate of deaths that resulted from 
smoking and exposure to secondhand smoke was approximately 440,000 annually [23].  
Cigarette smoke and oxidation 
Cells and tissues are vulnerable to oxidative damage; however due to the proximity and 
function of the lung epithelial tissues, the components of the cigarette smoke makes them more 
vulnerable to oxidative damage. The epithelial cells of the lungs can be damaged by cigarette 
smoke from direct interaction of its components [24, 25].  
Cigarette smoke is a complex mixture of over 4700 chemical compounds, including high 
concentrations of reactive oxygen species (ROS) and reactive nitrogen species (RNS) [26-30].  
Cigarette smoke contains epoxides, peroxides, nitric oxide (NO'), nitrogen dioxide, 
peroxynitrates, semiquinone, hydroxyl radical, and many other free radicals [29]. Besides the 
toxic components of cigarette smoke, lungs of cigarette smokers are further burdened by 
secondary oxidative stress triggered by ROS and RNS from cigarette smoke. It has been 
demonstrated that increased ROS and RNS levels leads to activation of transcription factors, 
signal transduction and gene expression of proinflammatory mediators which generates 
inflammation response. There are increased numbers of neutrophils and activated macrophages 
in the lungs of cigarette smokers [29, 30], and they are known to release large amount of 
hypochlorite, hydrogen peroxide and superoxide [31]. The inflammatory response and release of 
ROS under normal conditions is important in immune response. However, when the 
inflammation becomes chronic, the neutrophils and macrophages are perpetually activated, this 
creates severe oxidative damage to the cells and tissues of cigarette smokers [32], and that may 
predispose smokers to lung diseases.     
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Emphysema and cigarette smoke 
Pulmonary emphysema (PE) is disease characterized by progressive and irreversible 
destruction of the lung parenchyma; it is a cause for lot of morbidity and mortality. It belongs to 
class of disease clinically classified as a chronic obstructive pulmonary disorder (COPD) [33-
35].  In PE the air spaces distal to the terminal bronchiole are enlarged and alveolar walls are 
destroyed [36], as a result the lungs loses their elastic recoil force, which is required to drive the 
air out of the lungs. The volume airflow in the lungs is severely reduced due to loss of lung 
elasticity. PE can be subdivided into two types. Centrilobular emphysema, which is associated 
with cigarette smoke, is where there is dilation or destruction of bronchioles. Panlobular 
emphysema, which results from the deficiency of α1-antitrypsin [36], is characterized by dilation 
and destruction of acinus. Studies have shown that approximately 40% of heavy smokers 
develop PE over the span of four decades [37].         
α1-Antitrypsin is a 52-kDa glycoprotein that protects the lungs from elastic damage. It is 
the major antiprotease of alveolar region; it provides protease/antiprotease balance. Neutrophil 
elastase (NE), a serine protease, is capable of destroying structural components of the alveolar 
wall of the lungs, α1-Antitrypsin protects the lungs from NE.  In people with hereditary 
deficiency of serum antitrypsin have low concentration of α1-Antitrypsin in the blood, despite 
normal production by the liver. Due to low concentration of the enzyme in the blood, the 
required amount of α1-Antitrypsin is unable to reach the lungs, resulting in unopposed activity of 
protease, leading to systematic destruction of the lungs. People with this hereditary deficiency 
usually develop PE.    
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The relationship between smoking and PE has been established by many studies. In one 
study, elastase inhibitory activity between smokers and non smokers were compared based on 
the lung fluid obtained from the donors, the cigarette smokers had two fold reduction in their anti 
elastase ability compared to the non smokers [38].  The methionine residues are oxidized to 
methionine sulfoxides in α1-Antitrypsin  found in broncho alveolar lavage (BAL) fluid [39]. In 
order to understand the molecular basis of lowered anti elastase activity in cigarette smokers 
Taggard et al. studied the effect of hydrogen peroxide, found in cigarette smoke, on the 
methionine residues found in α1-Antitrypsin [40].  They found that the methionine residues were 
susceptible to oxidation. There are 9 methionine residues in α1-Antitrypsin, however only 2 
residues, methionine 351 and 358, are most susceptible to oxidation. Also, the oxidation of either 
Met351 or Met358 resulted in inactivation of α1-Antitrypsin. They produced recombinant α1-
Antitrypsins, where one or both met residues were substituted with valine. The recombinant 
proteins with single substitutions were not easily inactivated as the wild types, and the double 
mutant was resistant to oxidative damage.  They established that the oxidation of the 2 
methionine residues takes away the anti elastase capacity of α1-Antitrypsin. Combination of 
increased protease activity and proteases inactivation by oxidants have also been associated in 
diseases like cystic fibrosis, bronchopulmonary dysplasia, hyperoxia-induced lung damage, adult 
respiratory distress syndrome[40].  
Hemostasis and thrombomodulin 
The physiological process that stops bleeding, by formation of hemostatic plug, at the site 
of an injury while maintaining normal blood flow elsewhere in the circulation is referred as 
hemostasis [41]. The hemostasis can be divided into primary, secondary hemostasis and 
fibrinolysis [42]. Primary hemostasis is the primary response of the platelets towards an 
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endothelial injury.  In primary hemostasis, plugging of the injury results when platelets are 
activated and they bind to the site of injury and with each other. Platelets circulate in the blood 
for approximately 10 days and their concentration ranges from 100 to 400 million per milliliter 
of blood [43]. Under normal physiological conditions they do not aggregate with each other nor 
do they adhere to the surfaces. In the event of injury, several platelet receptors in presence of 
their corresponding ligands activate the platelets, which results in platelets aggregation and 
adherence to the injured site.     
 Secondary hemostasis consists of the generation of thrombin and insoluble fibrin, and 
subsequent deposition of fibrin into and around the platelets on the site of injury. The fibrin 
forms a crosslinked mesh that strengthens and stabilizes the clot [41].  The initiation of 
secondary hemostasis involves coagulation cascade of serine proteases that results in cleavage of 
soluble fibrinogen by thrombin. The presence of anticoagulants like thrombomodulin and 
heparan sulfate proteoglycans prevents the activation of serine proteins cascade in normal blood 
vessels. In the event of injury to the blood vessels, the blood gets exposed to tissue factor, which 
activates factor VIIa [44], which subsequently activates factor X. The factor X can also be 
activated by factor IXa in presence of factor VIIIa.  Prothrombin is activated by factor Xa in the 
presence of cofactor factor Va resulting in generation of thrombin [45]. Thrombin cleaves 
fibrinogen to produce insoluble fibrin. The coagulation cascade or waterfall model of proteolytic 
reactions was proposed in 1960s, and they are based on two complementary blood clotting 
models [46, 47]. This cascade has received general acceptance. The steps in the coagulation 
cascade look like Y-shape, with intrinsic and extrinsic pathway converging to form a common 
pathway at factor Xa. The coagulation cascade has been shown to be insufficient to predict 
bleeding tendency in vivo [48, 49]. In the past decade a cell based model of coagulation has been 
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proposed for the secondary hemostasis [48, 49]. This model consists of three phases: initiation, 
amplification, and propagation. During initiation there is production of prothrombinase on the 
cell surface the cells that express tissue factor, followed by production of low amounts of 
thrombin. During the amplification step thrombin activates the platelets and cofactors V and VII. 
In the propagation step, other platelets in the bloodstream are recruited on the site of injury, 
which leads to generation of large amounts of thrombin, which amounts production of fibrin to 
stabilize the platelet.   
The third facet of hemostasis is fibrinolysis. The coagulant tendency of the primary and 
the secondary hemostasis is counteracted by fibrinolysis. Plasminogen circulating in the blood is 
cleaved to produce plasmin by endothelial bound tissue-type plasminogen activator. Plasmin 
subsequently degrades fibrin and destroys the fibrin-platelet plug [50, 51].   
Blood coagulation is a delicate balance between anti thrombotic and pro thrombotic 
components, so the fibrin deposition and removal is tightly regulated, and defects in any of these 
components can either lead to thrombosis or excessive bleeding. Central to hemostasis is 
thrombin, a serine protease, which has created significant research interest, owing its ubiquity in 
hemostasis. As previously discussed, the end product of coagulation cascade is production of 
active thrombin, which catalyses the formation of fibrin from fibrinogen. Thrombin regulates the 
coagulation cascade through feedbacks. Besides its role in secondary hemostasis, thrombin also 
plays a vital role in primary hemostasis as an activator of platelets. Also, thrombin has long 
reaching effects on inflammation, cell survival, and cell proliferation [52]. It is very important to 
regulate the production of thrombin to maintain homeostasis.    
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Thrombomodulin, as the name indicates, modulates the activity of thrombin. Thrombin 
when bound to thrombomodulin activates protein C. Activated protein C proteolytically destroys 
coagulation factors Va and VIIIa and suppresses further thrombin formation. The binding of 
thrombin to thrombomodulin also activates the carboxypeptidase thrombin-activatable 
fibrinolysis inhibitor (TAFI) [53]. The activation of protein C and TAFI inhibits coagulation and 
fibrinolysis, making thrombomodulin key protein for the regulation of coagulation and 
fibrinolysis. Thrombomodulin is a protein cofactor that is found on the endothelial cell surfaces, 
at an approximate density of 50,000-100,000 molecules per cell [54], and it modulates the 
activity of thrombin [55, 56]. It was discovered by Esmon and Owen in the 1960’s. The path to 
their discovery started with the evidence of circulating thrombin activated protein, activated 
protein C, and its precursor. Those findings led them to realize the necessity of a cofactor that 
activates thrombin mediated activation of protein C.  In rats, it is found predominantly in the 
lungs when compared with kidney and liver [57].  Thrombomodulin, purified from human lung 
endothelial membrane preparations, had an apparent MW of 78,000 Da [55]. Encoded by an 
intronless gene, the mature single-chain glycoprotein in the human is 557 amino acids long. 
Structurally it has 5 distinct domains. It has a short cytoplasmic tail at the C-terminus, which 
anchors thrombomodulin. There are several potential sites for phosphorylation sites in the C 
terminus, in spite of that this region is not well conserved across different species [58]. The 
deletion of this tail in mice does not have any effect in development, survival, coagulation and 
inflammation [58]. There is a well conserved membrane-spanning domain, followed by a 
serine/threonine-rich domain with four potential sites for O-linked glycosylation. The 
serine/threonine region supports the attachment of chondroitin sulfate, which has 20 repeating 
disaccharide units and a terminal trisaccharide unit [59]. Adjacent to the serine/threonine-rich 
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region is a domain that has 6 epidermal growth factors (EGF)-like repeats, this domain is the best 
characterized. This region shows disulfide bonding pattern that is seen in a typical protein-
protein interactions. The activation of protein kinase C and mitogen-activated protein kinase 
(MAPK) is linked to this domain for promotion of cell division on cultured vascular smooth 
muscle cells fibroblasts. The data shows that this domain is associated with atherogenesis and 
proliferation, although the clinical significance has not been established [60, 61]. The first two 
EGF- like repeats, which are furthest from the serine/threonine rich region, their function 
remains unknown. EGF-like repeats 3, 4, 5, and 6 [62-64] have been studied in detail by several 
groups and are essential for activation of Protein C by thrombin-thrombomodulin complex. The 
cofactor function for thrombomodulin requires the last three of six tandemly repeated EGF-like 
domains (EGF 4, 5, and 6), as well as a Ser/Thr-rich domain between EGF-like domain 6 and the 
transmembrane domain. The residues 1 through 222 comprises N-terminal region of 
thrombomodulin, which constitutes almost half of the extracellular portion of the protein. This 
region has two potential sites for N-linked glycosylation and it also shares similarities with C-
type lectins. This lectin like domain has a compact hydrophobic core, two alpha-helices, two beta 
sheets and two disulfide bonds based on computer models [65]. The lectin like domain of 
thrombomodulin lacks carbohydrate recoginition domain as well as Ca
2+
 binding site unlike 
other C-type lectins. The residues 155 through 222 of thrombomodulin might be associated with 
plasma membrane and this region is hydrophobic [66].  The lectin like domain is suggested to be 
globular and furthest from the plasma membrane making it in the prime position to interact with 
other molecules, this results are based on electron microscopy and computer models [67]. This 
region plays major role in cell adhesion, inflammation and cell proliferation but it lacks anti 
coagulant function.  
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Thrombin binds to thrombomodulin to activate Protein C which initiates the cascade that 
stops clotting, by inactivation of clotting factors Va and VIIIa [68]. The thrombin- 
thrombomodulin complex activates protein C 1,000-fold more when compared to activation of 
protein C by thrombin alone.  Deficiency in protein C or activated protein C is well established 
as increasing the risk of thrombosis [69]. Low levels of thrombomodulin are a well established 
risk factor for heart disease [70, 71]. Without a doubt, thrombomodulin plays a key role in 
slowing or stopping clotting. It has been shown that thrombomodulin in complex with thrombin 
activates thrombin activatable fibrinolysis inhibitor (TAFI) by 1250 fold [72-75].  Activated 
TAFI is  a plasma procarboxypeptidase B that stabilizes clot by down regulating fibrinolysis 
[76]. Activated TAFI catalyzes the removal of lysine residues from the C-terminal of fibrin [77, 
78], resulting in elimination of plasminogen binding site of fibrin, subsequently plasminogen is 
unable to activate and prevention of fibrinolysis [79, 80] .  This function of thrombomodulin 
might seem contradictory to its pro-fibrinolytic function previously discussed, but this highlights 
that thrombomodulin is a key regulator in coagulation, since it controls the formation and 
breakdown of clots.  
Thrombomodulin is anchored on the luminal surface of the endothelium and as 
previously indicated, thrombomodulin lacking the cytoplasmic domain appeared normal [58]. 
Thrombomodulin undergoes endocytosis and degradation, and a significant amount of it is 
cleaved off and it is found in blood. Thrombomodulin found in blood are heterogeneous in size, 
due to differences in glycosylation [81, 82]. Four different fragments have been isolated from 
blood and seven fragments ranging in size from 12 to 100kDa after reduction of disulfides [83] . 
The concentration of thrombomodulin in serum and plasma are reported to be between 3 to 300 
ng/mL [84]. In diseases like diabetes and lupus high levels of thrombomodulin in plasma have 
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been reported [85], this is believed to be a good marker for endothelial damage [53].  Studies 
have correlated high plasma thrombomodulin levels to be associated with a low risk of 
developing coronary heart disease [53]. 
As previously mentioned, thrombomodulin has 6 epidermal growth factor (EGF) like 
domains. Generally, EGF-like domains have 40 amino acid residues, and six cysteine resides that 
form three disulfide bonds [86]. Individual EGF like domains were synthesized and only the fifth 
domain bound to thrombin by itself [87]. The fourth and the fifth EGF like domains consists of 
81 amino acids, and the fifth domain contains most of the residues that bind to thrombin. The 
EGF like domain 4 and 5 (TMEGF45) bind to thrombin more tightly than EGF 5 alone. 
TMEGF45 is the smallest fragment of thrombomodulin that when bound to thrombin can 
activate protein C. Addition of fourth and the fifth EGF-like domains separately, do not activate 
protein C, suggesting they work together in activation of protein C [88].  The kcat values for 
protein C activation by the thrombin-TMEGF45 complex, calculated by binding kinetic studies 
and cofactor activity assays, shows TMEGF45 has full cofactor activity. The EGF like domain 
six increases the Km value of thrombomodulin for thrombin by factor of ten, despite not altering 
the Kcat value of  thrombin-thrombomodulin complex for protein C [89].   The EGF 4 and 5 of 
thrombomodulin is linked together by three residues, and one of them is methionine, which is the 
388
th
 residue in thrombomodulin (Met388) [90]. Figure 1.1 is thrombomodulin residues from all 
mammals sequenced as of the date of writing; Met388 is conserved in all the sequences. 
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Figure 1.1: Alignment of region of interest of thrombomodulin amino acid sequences from 
different mammals. Methionine 388 is conserved in all these organisms.  
 
 The mutation of Met388 to any other residues, except leucine, decreases the 
anticoagulant cofactor activity of thrombomodulin [91]. More importantly, there is 76-90% loss 
of activity when Met388 is oxidized using H2O2 [92].  There are four other methionines in 
thrombomodulin, but their oxidation does not disrupt the ability to activate protein C [92]. The 
Kd of thrombomodulin thrombin interaction increases to 10.9 from 4.4nM, when a full length 
thrombomodulin had oxidized Met388 [93]. TMEGF45 with oxidized Met388 has 3.5 fold lower 
Kcat, and 3.3 fold higher Km values when compared to wild type TMEGF45 based on protein C 
activation assays [94]. It must also be mentioned that clot stabilizing activation of TAFI by 
thrombin-thrombomodulin complex is unaffected by the oxidation of Met388 [95]. Since the 
activation of clot stabilizing activated TAFI, a procoagulant pathway, is unaffected by Met388 
oxidation, while activation of protein C, an anticoagulant pathway, is suppressed by oxidation of 
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEG  Homo sapiens Human
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTRGNCECPDG  Saimiri sciureus Squirrel monkey 
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEG  Pan troglodytes Chimpanzee 
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEG  Pan paniscus Bonobo
LNQTSYLCVCAEGFAPIPHQPHRCQMFCNQTACPADCDPNTQANCECPEG  Nomascus leucogenys Nor. white-cheeked gibbon 
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTRGNCECPDG  Macaca mulatta Rhesus monkey
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTRGNCECPDG  Papio Anubis Olive Baboon
LGQTSYRCICAEGFAPVPQQPHRCQMFCNQTACPADCDPNTKSNCECPEG  Callithrix jacchus Common marmoset
LGQTSYRCICAEGFAPVPQEPHRCQMFCNQTACPADCDPNTKSNCECPEG  Saimiri boliviensis Black-capped squirrel monkey
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTRGNCECPDG  Macaca fascicularis Crab-eating macaque
VGQTDYHCICAEGFAPSPHDPHRCQMFCNQTACPADCDPNSPTSCQCPEG  Ailuropoda melanoleuca Giant Panda
LGHTGYRCVCAEGFAPNPLDPHRCQMFCNETACPADCDPNSLDSCQCPDG  Loxodonta africana African bush elephant
LNQTSYLCVCAEGFAPVPHEPHRCQMFCNQTACPAVCDSNTQANCECPEG  Pongo abelii Sumatran orangutan
VSQTDYRCICAEGFAPVPHDPHRCQMFCNQTACPADCDPNSPTSCQCPEG  Canis familiaris Dog
VGPTNYTCICAEGFVPKPQEPSRCQMFCNQTSCPADCDPNTPADCKCPEG Otolemur garnettii Greater galago
VGQTDYRCICAEGFAPSPHDPQRCLMFCNQTACPADCDPYSPTSCQCPEG Mustela putorius furo Ferret
VGQNDYRCICAEGFVPSPQAPHRCQMFCNQTTCPADCDPNNPDSCQCPDG Felis catus Cat
VGRTGYRCVCAEGFAPVPHAPHRCQMFCNQTSCPADCDPNKQDSCQCPDG  Sus scrofa Pig
VGRSEHKCICAEGFAPVPGAPHKCQMFCNQTSCPADCDPHYPTICRCPEG  Bos taurus Cow
VSPTDYRCICAPGFAPKPDEPHKCEMFCNETSCPADCDPNSPTVCECPEG  Mus musculus Mouse
VNSTHYNCICAEGFAPKLDDPDRCEMFCNETSCPADCDPNSPSFCQCPEG  Rattus norvegicus Rat
VSPTEYICICAEGFAPKPGEPHRCEMFCNESSCPADCDPNTPDFCHCPEG Cricetulus griseus Chinese hamster
LGQ-NYRCICAEGFAPVPDEPHRCQMFCNQTTCPADCDPNYPSTCLCPEG  Oryctolagus cuniculus Rabbit
VGRSEHQCICAEGFAPVPGAPHKCRMFCNQTSCPADCDPHNPAVCWCPEG Ovis aries Sheep
VGHTNYQCVCAEGFVPNAHDPHRCQMFCNTTSCPADCDPNNPATCQCPEG Pteropus alecto Black flying fox
VGTDKYECICAEGFIPNPKEPYRCQMFCNQTECPADCDPNNLNICYCPEG Heterocephalus glaber Naked mole rat
VGRSEHKCICAEGFAPVPGAPHKCRMFCNQTSCPADCDPHYPTICRCPEG Bos grunniens mutus Yak
VGQTDYRCICAEGFAPSLQDPHRCRMFCNQTSCPADCDPNTPGSCQCPEG Tupaia chinensis Tree shrew
LKET*YRCICAEGFAPVPHAQHKCQMFCNQTECPADCDPNYPDICRCPDG Myotis davidii David’s myotis
VGQNDYRCICAEGFAPIPQDPDRCQMFCNQTACPADCDPNNPSNCQCPEG  Equus caballus Horse
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Met388. Although effects oxidation of Met388 on activation of protein C and TAFI were 
demonstrated in vitro, it seems that oxidation of Met388 leads hemostasis towards pro 
coagulation, and higher rates of formation of clots when significant amounts of Met388 is 
oxidized.         
 
Figure 1.2: Schematic diagram of TMEGF45. It consists of 81 amino acids. The fifth domain 
contains most of the residues that bind to thrombin. TMEGF45 is the smallest fragment of 
thrombomodulin that when bound to thrombin can activate protein C. 
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The structures TMEGF45 and TMEGF456-thrombin complex have been investigated 
using NMR to understand the interactions of Met388 [94] in thrombomodulin. Met388 plays at 
least two structural roles. First, Met388 is important part of the fifth domain’s hydrophobic 
region, and there is disruption of the hydrophobic interactions when the methionine is oxidized 
to methionine sulfoxide. Second, the interaction between the fourth and the fifth domain of 
thrombomodulin is mediated by methionine, and conversion to methionine sulfoxide has 
potential to disrupt the orientation of the two domains. There is a significant structural difference 
between oxidized and non oxidized forms in the fifth domain of thrombomodulin. Phenylalanine 
376, located in the fourth domain, packs against the hydrophobic methionine but occupies a 
substantially different position when the hydrophilic sulfoxide form is present, making it a key 
part of the conformational switch.  These structural changes bury several residues which interact 
with thrombin in the structure of the thrombomodulin-thrombin complex [96].  
 
 
Figure 1.3: Structure of Methionine and Methionine Sulfoxide 
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Is a decrease in thrombomodulin activity biologically relevant? 
As mentioned previously, in vitro studies have shown that oxidation of Met388 leads to 
decrease of thrombomodulin anticoagulant cofactor activity. But is this decrease in activity 
biologically relevant? Could there be sufficient thrombomodulin in reserve, so that oxidation to 
some of the thrombomodulin is inconsequential? In a study conducted in mices, the intronless 
thrombomodulin gene was deleted to create a model for thrombotic disease [97]. The study 
found complete absence of thrombomodulin resulted in death of embryos at day 9.5, the death 
preceded before the functional cardiovascular system was assembled. In another study in mice, 
glutamate at position 387, which is the part of the linker region connecting EGF like domain four 
and five of thrombomodulin, was replaced with proline [98]. The Met388 is adjacent to 
glutamate 387, which make this study relevant to our hypothesis. This study found there was a 
decrease in the ability of mutant protein to activate protein C. The kcat was 37% of wild-type, Kd 
for thrombin was down by a factor of 45, and Km for protein C was increased by 1.6 fold. The 
amount of thrombomodulin purified, decreased by factor of three, possibly due to decreased 
amount of proteins expression on the cell surface or due to turnover increase. The cell culture 
experiments showed that mutant endothelial cells ability to activate protein C was reduced by 38 
fold when compared to wild type cells. Despite the significant decrease in the activation of 
protein C in the recombinant animals, they were viable and reproduced normally. However, these 
animals showed cardiovascular diseases reminiscent symptoms, they had fibrin deposition and 
small blood clots in lungs, spleen and the heart [99]. The fibrin deposition was tenfold more in 
the recombinant mice when compared with normal mice at three to 6 months of age [100]. 
Myocardial infarction is a common and potentially fatal consequence of thrombosis resulting 
from imbalance of fibrin deposition and removal [101].  In the follow up to the recombinant 
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thrombomodulin study, it was shown that the recombinant mice were in hypercoagulable state 
with a tendency towards sepsis and thrombosis. Such conclusion was inferred from accelerated 
rate of platelet dependent thrombus formation after FeCl3 induced endothelial injury was 
subjected to the carotid artery [102]. 80% of recombinant mice showed full thrombotic occlusion 
when subjected to FeCl3 treatment, alternatively only 27% of the wild type mice showed such 
symptoms [102].   The carotid arteries of recombinant and wild-type mice were permanently 
blocked near carotid bifurcation by ligation. These animals recovered from surgery without any 
complications. The recombinant mice showed severe thrombotic occlusion which spanned over 
the entire length of the artery, whereas wild type mice showed thrombotic occlusion within 1mm 
from the ligation site [102]. When injected with lipopolysaccharide to induce infection, in 
recombinant mice resulted in much higher fatality compared to the wild-type, also in the mutant 
mice fatality occurred much earlier when injected with lipopolysaccharide [102].    
Prolylcarboxypeptidase (PRCP) is an endothelial membrane-bound serine 
carboxypeptidase responsible for activation of bradykinin and angiotensin [103-105]. Both 
proteins regulate the vascular NO to provide protection from thrombosis. PRCP is indirectly 
involved in maintenance of normal blood pressure and reduction of thrombosis risk. PRCP 
polymorphism has been associated with hypertension and inflammation [106]. PRCP gene-
trapped mice are hypertensive and are prone to faster thrombosis [107]. These mice have 
increased in vivo vascular ROS and uncoupled endothelial nitric oxide synthase (eNOS) and 
reduced expression of vascular thrombomodulin in their aorta [108-110]. The hypertensive and 
prothrombotic state in PRCP gene trapped mice was abrogated by antioxidant treatment. This 
shows the hypertensive and prothrombotic state arose from high levels of ROS in PRCP gene 
trapped mice. More importantly, the knockdown of PRCP by silencing RNA (siRNA) in Human 
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umbilical vein endothelial cells (HUVECs) resulted in increased uncoupled eNOS and 90% 
reduction in Protein C activation. The data obtained from thrombomodulin antigen showed no 
significant change (p= 0.30) in expression of thrombomodulin in siRNA knockdowns of PRCP 
HUVECs [107]. The thrombomodulin was expressed but it was unable to activate Protein C. The 
paper speculates that the inactivation of Protein C could caused by ROS inactivation of critical 
methionine for functionality of thrombomodulin. This paper demonstrates that oxidation caused 
by high level of ROS prevents thrombomodulin from activation of Protein C in a semi in vivo 
environment (HUVECs).   
The most common cardiovascular diseases seen in smokers are myocardial infarction and 
stroke. The blood of smoker is more prone to clot than non smoker; they are in hypercoagulable 
state. The narrowing of the arteries resulting from atherosclerosis increases the possibility of 
cardiovascular diseases [111], equally important is the hypercoagulable state seen in smokers. 
The fact that smokers have a hypercoagulable state has been established; however, despite 
intensive research the molecular origin of such a state has not been shown. Free radical mediated 
oxidative damage to the endothelium is considered to be an important factor for the development 
of cardiovascular diseases in smokers. Most of the research in this area has been focused on 
nitric oxide signaling impairment caused by oxidation [112-114]. As in emphysema, where 
oxidation of key methionine residues is the molecular basis of the disease, it is our belief that 
similar oxidation is taking place in the methionine 388 of thrombomodulin in cigarette smokers 
from the oxidation that occurs from smoking. We strongly believe that oxidation of methionine 
388 in thrombomodulin is an important molecular factor leading to cardiovascular diseases in 
smokers.        
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As was mentioned earlier in this chapter, thrombomodulin is predominantly located in the 
lungs [115, 116] making it more vulnerable to oxidants found in cigarette smoke. The oxidants 
secreted by immune cells in the lungs in response to cigarette smoke, makes lung endothelium 
very oxidizing. It must be pointed out that oxidation of methionine in smokers and non smokers 
have not been measured so far, however the plasma levels of thrombomodulin in smokers and 
non smokers have been examined. 
It has been shown that high levels of cigarette smoke exposure causes decrease in 
activated protein C, and there was direct correlation between the levels of protein C with the 
degree of cigarette smoke exposure [117].  This study found that activated protein C circulating 
in the blood were 23.3% lower in smokers than in non smokers. There could be several factors 
that contribute towards the low level of activated protein C in smokers, but based on the 
evidences we have seen so far; it seems very likely that methionine oxidation of thrombomodulin 
causes lower activation of protein C in smokers. Venous thromboembolism has been strongly 
linked to low levels of activated protein C [118, 119], also low levels of activated protein C are 
considered to be a risk factor for ischemic stroke [120]. The comparison of protein C levels in 
smokers and non smokers, and relation between thromboembolism and ischemic stroke study 
strengthens our case for a link between thrombomodulin oxidation and cigarette smoke as an 
important molecular cause of cardiovascular diseases.  
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CHAPTER 2: METHODS EXPLORED FOR QUANTIFICATION OF METHIONINE 388 
OXIDATION IN HUMAN URINARY THROMBOMODULIN 
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Introduction  
In the first chapter we hypothesized that the methionine 388 of thrombomodulin is more 
oxidized in cigarette smokers than in non smokers. We speculated that this could be the key 
molecular mechanism behind the prothrombotic state seen in smokers, hence, an important 
contributor towards the development of cardiovascular disease in smokers. In order to quantify 
the oxidation of methionine in thrombomodulin isolated from urine, a rapid method of isolation 
of the protein is necessary to process a reasonable number of samples and minimize any 
oxidation during processing. In this chapter we will discuss the method we have developed to 
quantitate the methionine 388 oxidation in thrombomodulin, as well as the other methods that 
were attempted. 
Thrombomodulin is critically important for hemostasis [121-124]. As the name implies 
thrombomodulin serves to regulate the activity of thrombin. The thrombomodulin-thrombin 
complex activates protein C, and the activation results in degradation of the factors that promote 
clotting cascade [125]. The activated protein C or deficiency in protein C has been linked to 
increased risk of thrombosis [126-128]. Low levels of thrombomodulin have been established as 
a risk factor for heart diseases [71, 129, 130]. Thrombomodulin is also involved in activation of 
activatable fibrinolysis inhibitor (TAFI). Thrombin when complexed with thrombomodulin 
activates TAFI, activated TAFI stabilizes clot [76]. It is worth reflecting on this point that 
thrombomodulin controls the rate of formation of clot as well as its breakdown.    
Thrombomodulin is anchored on the luminal surface of the endothelium [131, 132]. It is 
found in at much higher levels at the lungs of rats compared in kidney or liver [115, 133, 134]. 
The trans membrane helix and the C-terminal cytoplasmic domain of thrombomodulin anchors 
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the protein and they have not been demonstrated to have direct functional role to hemostasis. 
Mice lacking the cytoplasmic domain appeared normal besides the elevated levels of 
thrombomodulin in the plasma [58, 135]. Significant amounts of thrombomodulin is cleaved off 
from the surface and it circulates in the blood [136, 137]. The thrombomodulin circulating in the 
blood is not homogenous in size partly due to the differences in glycosylation [138, 139] and 
mostly due to variation in proteolysis of thrombomodulin. Four different protein fragments have 
been isolated from plasma, and following reduction of disulfides, seven fragments that range 
from 12 to 100 kDa in size have been isolated [121, 140, 141]. These fragments are able to 
activate protein C when complexed with thrombin, however their activity drops to 16-50% when 
compared to the membrane bound intact thrombomodulin [142]. The literature values for 
thrombomodulin in serum and plasma has been reported to be between 3 to 300 ng/ml [84, 121, 
143, 144]. High concentrations of thrombomodulin are a good indicator of endothelial damage 
and have been reported in many diseases and conditions like lupus, preeclampsia, and diabetes 
[145].      
In vitro oxidation of methionine 388 of thrombomodulin has been shown to lower the 
ability of thrombin-thrombomodulin complex to active protein C [146]. When the methionine 
388 was substituted with leucine, the mutant was insensitive to oxidation and it activated protein 
C [147, 148]. The oxidation of methionine 388 in thrombomodulin has been shown to have no 
effect on TAFI activation by thrombomodulin-thrombin complex [149]. Since oxidation of 
methionine 388 promotes clotting by lowered activation of protein C and has no effect in the clot 
stabilizing by TAFI, methionine 388 oxidation of thrombomodulin in humans should be a factor 
promoting hypercoagulable state. 
24 
 
There is good reason to try to determine how much oxidation of this amino acid side 
chain actually occurs in vivo.  The quantification of urinary thrombomodulin methionine 388 
oxidation involves 3 three major steps: 1) purification of thrombomodulin from urine, 2) 
digestion of purified thrombomodulin 3) quantification of methionine oxidation. In this chapter 
we report several methods that were tested to arrive at a protocol to successfully perform the 
aforementioned three major steps.        
Materials and Methods:  
Purification of thrombomodulin    
Detection of thrombomodulin by ELISA 
The concentration of thrombomodulin in various fractions throughout the course of 
purification was followed using a commercially available sandwich enzyme linked 
immunoabsorbant assay (ELISA) kit for thrombomodulin (American Diagnostica, Greenwich, 
CT).   
Urine sample collection 
The University of Arkansas Institutional Review Board approved all experimental 
protocols using human subjects.  Samples of the first morning urinate were collected by 
volunteers in 400 mL centrifuge bottles. Thiodiglycol (5 mL) and 0.5 M EDTA (1 mL, pH 8.0) 
were added to containers before sample collection.  The collected samples were transported 
using an insulated bag containing an ice pack. The samples were generally transported to the 
laboratory within two hours of collection and stored at 4 °C for no longer than 2 hours before 
further processing to minimize the opportunity for oxidation. Typical volumes of the sample 
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from a donor ranged from 200-550 mL. Prior to processing, 1 mL of sample was removed and 
stored in -80°C for determination of the initial thrombomodulin concentration in the sample.   
Jumbosep spin filter 
Jumbosep spin filters were tested for the concentration of the urine sample. The 
Jumbosep centrifugal device (Pall) consists of sample reservoir, membrane filter insert, and the 
filtrate receiver. The sample reservoir has a maximum capacity of 60 mL. The membrane filters 
are constructed from modified polyethersulfone on polyethylene substrate, and they are low 
protein binding. A membrane filter with molecular weight cut off of 30 kd was used for 
purification. 60 mL of urine sample that was previously cooled at 4 °C, and centrifuged in 
Sorvall GS-3 rotor at 4,000 rpm for 30 min at 4 °C was added to the sample reservoir. The 
Jumbosep filter was centrifuged at 3500 rpm in a SH-3000 rotor for 30 minutes at 4 °C. After 
centrifugation for 30 minutes, the filtrate was removed and more urine sample was added to the 
sample reservoir and centrifuged. The previous step was repeated until entire urine sample was 
passed through the filter, and the final volume in the reservoir was 20 mL. Next, buffer exchange 
was performed to adjust pH and the ionic strength of the urine concentrate. 40 mL of 25 mM 
imidazole acetate at pH 5.5 was added to the sample reservoir, and the Jumbosep filter was 
centrifuged for 30 minutes. The buffer exchange was repeated two more times. The buffer 
exchanged concentrated urine sample was collected for downstream processing. Slurry of SP 
Sepharose FF was poured into a 12 mL Econo-Pac gravity-flow polypropylene column in a 
sufficient amount to pack a 1 ml bed volume. The column was equilibrated using 10 mL of 25 
mM imidazole acetate, pH 5.5. Urinary protein concentrate following Jumbosep was passed 
through the column, and the column was washed with 3 mL of 25 mM imidazole acetate, pH 5.5. 
The flow through and the wash from the SP Sepharose column was collected in 50 mL conical 
26 
 
flask. Slurry of Q Sepharose FF was poured into a 12 mL Econo-Pac gravity-flow polypropylene 
column in a sufficient amount to pack 2 ml bed volume. This column was equilibrated using 10 
mL of 25 mM imidazole acetate, pH 5.5. The pooled flow through and wash from the SP 
Sepharose was passed through the Q Sepharose column. The column was washed with 8 mL of 
25 mM imidazole acetate, pH 5.5. Thrombomodulin was eluted by passing 8 mL of 0.5 M NaCl, 
20 mM imidazole acetate, pH 5.5 through the column, elutes were collected in one mL fractions.  
The crude thrombomodulin typically eluted in the fourth through sixth fractions.  The fractions 
containing thrombomodulin, tested using ELISA, were flash frozen in liquid nitrogen and 
lyophilized. The dried samples were stored at -20 °C or immediately subjected to HPLC 
purification.    
Tangential flow filtration (TFF) system 
   Labscale Tangential Flow Filtration (TFF) System, manufactured by Millipore, was 
tested for the concentration of the urine sample. The Labscale TFF System has a graduated 
500 mL acrylic reservoir with a retentate backpressure valve, feed and retentate pressure 
indicators, and a stirrer assembly. A Pelicon XL filter with 30 kd MW cutoff Biomax membrane 
was attached to the TFF system. The urine sample cooled at 4 °C, and centrifuged in Sorvall GS-
3 rotor at 4,000 rpm for 30 min at 4 °C was poured into the TFF reservoir. The sample was 
concentrated until the urine sample was concentrated to the final volume of approximately 25 
mL. 400 ml of 25 mM imidazole acetate buffer pH 5.5 was added to the concentrate, and this 
solution was concentrated to 20 mL to exchange the salts from the urine. The buffer exchange 
was repeated until the sample was clear. Slurry of SP Sepharose FF was poured into a 12 mL 
Econo-Pac gravity-flow polypropylene column in a sufficient amount to pack a 1 ml bed volume. 
The column was equilibrated using 10 mL of 25 mM imidazole acetate, pH 5.5. Urinary protein 
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concentrate following Jumbosep was passed through the column, and the column was washed 
with 3 mL of 25 mM imidazole acetate, pH 5.5. The flow through and the wash from the SP 
Sepharose column was collected in 50 mL conical flask. Slurry of Q Sepharose FF was poured 
into a 12 mL Econo-Pac gravity-flow polypropylene column in a sufficient amount to pack 2 ml 
bed volume. This column was equilibrated using 10 mL of 25 mM imidazole acetate, pH 5.5. 
The pooled flow through and wash from the SP Sepharose was passed through the Q Sepharose 
column. The column was washed with 8 mL of 25 mM imidazole acetate, pH 5.5. 
Thrombomodulin was eluted by passing 8 mL of 0.5 M NaCl, 20 mM imidazole acetate, pH 5.5 
through the column, elutes were collected in one mL fractions.  The crude thrombomodulin 
typically eluted in the fourth through sixth fractions.  The fractions containing thrombomodulin, 
tested using ELISA, were flash frozen in liquid nitrogen and lyophilized. The dried samples were 
stored at -20 °C or immediately subjected to HPLC purification.    
Ion exchange chromatography  
The urine sample that was previously cooled at 4 °C was centrifuged in a Sorvall GS-3 
rotor at 4,000 rpm for 30 min at 4°C. The supernate was then filtered using a bottle-top 0.22 µm 
polyethersulfone (PES) membrane filter to remove remaining particulates and cellular debris. 
Sufficient 0.25 M imidazole buffer, pH 6.0 was added to the urine filtrate to bring to a final 
concentration of 25 mM imidazole acetate. Next, the pH of the sample was adjusted to 6.0 by 
addition of 2 M acetic acid or 6 M NaOH depending on the urine sample. Typically after the 
addition of 0.25 M imidazole buffer, the pH of the samples ranged from pH 5.5-6.4. The pH of 
the sample was measured using a pH electrode. A slurry of Q Sepharose FF (GE Healthcare) was 
poured into a 50 mL Bio-Rad Econo column in sufficient amount to pack a 20 ml bed volume. A 
Fluid Metering, Inc (FMI) pump was connected to the Bio-Rad column to pump buffer and urine 
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sample through the Q Sepharose column at a constant speed of 5 mL/min. The column was first 
equilibrated with 60 mL of 25 mM imidazole acetate, pH 6.0. Next, the urine sample was passed 
through the column. The column was washed with 50 mL of 25mM imidazole acetate, pH 6.0 
and then by addition of 20 mL of 25 mM imidazole acetate buffer, pH 6.0, 50 mM NaCl. 
Fractions containing thrombomodulin were eluted by addition of 50 mL of 25 mM imidazole 
acetate buffer, pH 6.0, 0.5 M NaCl. The 0.5 M NaCl fractions were collected in 15 mL conical 
tubes, 5 mL in each tube. The eluent after addition of 25 mL of 25 mM imidazole acetate buffer, 
pH 6.0, 0.5 M NaCl, tested positive for thrombomodulin. A solution of 0.2 M L-methionine 
(Sigma-Aldrich) was added to thrombomodulin containing fractions to a final concentration of 2 
mM methionine. The fractions were transferred to 1.5 mL microcentrifuge tubes, typically 14 
tubes, and flash frozen in liquid nitrogen. The frozen eluents in 1.5 mL microcentrifuge tubes 
were dried under vacuum in a SpeedVac concentrator system using medium heat (45°C).   
Multiple urine samples were collected from each donor since there was usually not 
enough thrombomodulin isolated from a single sample to reliably observe it by mass 
spectrometry.  Typically, three different urine samples were collected from each donor. These 
three samples were usually collected from each donor on consecutive days. Each sample was 
purified by ion exchange the very day it was collected. The thrombomodulin containing fractions 
were flash frozen, and were stored in -20 °C.  The thrombomodulin containing HPLC fractions 
from different samples were pooled before chymotrypsin digestion.    
Reverse phase HPLC purification. 
The dried samples from Jumbosep filtration, TFF, or ion exchange were dissolved in 
minimum volume, generally 5 mL of total volume, of 18.2 megohm deionized water. The 
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dissolved sample was passed through a 25 mm syringe filter with 0.2 µM PES membrane 
(VWR).  The 4 sets of 1.375 mL redissolved sample were injected into reverse phase Waters 
HPLC system. An Atlantis dC18, 5 μm particle, 4.6x250 mm column held at 58 °C and a 2996 
photodiode array detector monitoring 214 nm and 254 nm was used. Upon injection, a gradient 
was run at 1 mL/min from 10 to 29% acetonitrile, 0.1% trifluroacetic acid over 12 minutes, and 
then from 29% to 40% acetonitrile over the next 11 minutes, and then from 40% to 90% 
acetonitrile over the next 25 minutes. The eluents were collected in 1 mL fractions in 1.5 mL 
eppendorf tubes, to which were previously added 100 uL of 200 mM Tris buffer, pH 8.0. The 
thrombomodulin containing fragments, identified by ELISA, eluted at 30 minute. The HPLC 
method for purification of thrombomodulin was developed by Dr. Jeffery Froude, former 
graduate student in Stites Lab. His method was used as a template to develop the current method. 
The two methods differ in their gradient profile, the new method provides a better resolution of 
the thrombomodulin containing peak. The thrombomodulin containing 1.5 mL microfuge tubes 
were flash frozen in liquid nitrogen, dried under vacuum in a SpeedVac concentrator system 
using medium heat.  The HPLC Atlantis column was cleaned using 1.0 mL/min of 90% 
MeCN/0.1% TFA for 10 minutes, followed by equilibration to the starting conditions of 1.0 
mL/min of 10% MeCN/0.1% TFA in preparation for the next injection. 
 
Digestion of thrombomodulin 
Digestion using manufacturer’s protocol 
The thrombomodulin containing fractions from the reverse phase chromatography was 
pooled and dissolved in approximately 100 uL of 1X phosphate buffered saline (PBS; 1.46 mM 
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KH2PO4, 9.9 mM Na2HPO4, 2.68 mM KCl, 137 mM NaCl, pH 7.4). If the solution did not turn 
clear after the addition of the buffer, the sample was spun in a microcentrifuge (Galaxy 14D 
VWR) at 13K RPM for a minute. The supernatants were removed, and precipitates were 
dissolved in 75 µL of 1X phosphate buffered saline. Freshly prepared tris-
carboxyethylphosphine (TCEP) was added to make the final concentration of 50 mM TCEP. 10 
µL of 0.5 M sodium phosphate buffer pH 7.5 added to the sample, prior to addition of 500 units 
of PNGase F (New England Biolabs). The samples were incubated with gentle shaking at 37 °C 
for 2 hours to deglycosylate the sample. The protein was then digested at 30 °C for 8 hours after 
adding 4.1 μg of sequencing grade chymotrypsin (Princeton Separations) dissolved in 50 mM 
Tris-HCl, 1 mM CaCl2, pH 8.0. The chymotrypsin was inactivated by placing the samples in a 
100 °C dry bath for 30 seconds. The samples were immediately flash frozen, and stored in -20 °C 
until further processing.   
Digestion using urea  
The dried thrombomodulin containing HPLC fractions were redissolved in freshly 
prepared 150 µL 45 mM sodium phosphate buffer, 2.5 M urea pH 7.75. Freshly prepared 1 M 
TCEP was added to the final concentration of 10 mM. The sample was incubated in room 
temperature for 10 min. The sample was placed in a 65 °C heat block for 10 min, then 
immediately cooled on ice. 50 units of PNGase F (2 µL) was added to the sample and incubated 
at 37 °C for 4 hours. 5 µg of sequencing grade chymotrypsin was dissolved in 5 µL of 50 mM 
Tris-HCl pH 8.0, 1 mM CaCl2. The dissolved chymotrypsin was added to the sample and 
incubated in room temperature for 4, 12, or 36 hours.  
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   Alternatively, thrombomodulin digestion was conducted using minimal volume of 45 
mM sodium phosphate buffer, 8 M urea pH 7.75. The volume of buffer used ranged from 100 – 
150 µL.  Freshly prepared TCEP was added to the final concentration of 10 mM. The sample 
was placed on 100 °C heat block for 20 min, then immediately cooled on ice. The concentration 
of urea was decreased from 8 M to 4 M by addition of 45 mM sodium phosphate buffer, pH 7.75. 
50 units of PNGase F was added to the sample and incubated at 37°C for 4 hours. 10 µg of 
sequencing grade chymotrypsin was added to the sample and incubated in room temperature for 
24 hours. 
Digestion using acetonitrile 
The dried thrombomodulin containing HPLC fractions were resuspended in 100 µL of 
80% acetonitrile/20% 50 mM Tris-HCl/10 mM CaCl2 pH 8.0 buffer solution. Freshly prepared 
0.1 M TCEP was added to the final concentration of 10 mM. The sample was incubated in room 
temperature for 10 minutes. 50 units of PNGaseF was added and incubated at 37 °C for 1 hour. 5 
µL of fresh sequencing grade chymotrypsin (1µg/µL) was added and incubated for 4- 24 hours. 
This experiment was repeated with acetonitrile concentration at 20, 40, and 50%.  
Digestion using Invitrosol  
The Invitrosol LC/MS Protein Solubilizer (Invitrogen Corporation) was purchased to 
assist in thrombomodulin digestion. This proprietary surfactant blend claimed to solubilize 
hydrophobic proteins, not interfere with protease activity, and be compatible with reverse-phase 
high pressure liquid chromatography separations of digested peptides.  The dried 
thrombomodulin containing HPLC fragments were reconstituted in 90 µL of 25 mM ammonium 
bicarbonate, pH 8.0. 10 µL of 5X Invitrosol was added, and sonicated for 10 min. The solution 
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was heated for 15 min at 60°C, and then cooled to room temperature by placing it on ice. Freshly 
prepared 0.1 M TCEP was added to the final concentration of 10 mM. The solution was 
incubated for 20 min at room temperature. 50 units of PNGaseF was added and incubated at 37 
°C for 4 hour. 5 µL of fresh sequencing grade chymotrypsin (1µg/µL) was added and the sample 
was incubated for 12 hours at room temperature. The supernatant was removed and injected into 
the waters HPLC. 
Digestion using RapiGest  
RapiGest SF (Waters Corporation) is a reagent used to enhance the in-solution digestion 
of proteins. It enhances the digestion of proteins by making the proteins more soluble in solution.  
0.1 % (w/v) solution of RapiGest SF was prepared by dissolving 1 mg of lyophilized RapiGest 
SF in 1 mL of 50 mM ammonium bicarbonate buffer, pH 8.0. The dried thrombomodulin 
containing HPLC fragments were dissolved in 50 µL of 0.1 % RapiGest SF solution. Freshly 
prepared 0.1 M TCEP was added to the final concentration of 10 mM. The solution was heated 
for 10 min at 100°C, and then cooled to room temperature by placing it on ice. 50 units of 
PNGaseF was added and incubated at 37 °C for 4 hour. 5 µL of fresh sequencing grade 
chymotrypsin (1µg/µL) was added and the sample was incubated for 12 hours. TFA was added 
to the final concentration of 0.5%, and incubated at 37°C for 30 minutes to cleave the RapiGest 
SF. The sample was centrifuged at 13, 000 rpm for 10 minutes. The supernatant was removed 
and injected into the HPLC. 
Digestion using RapiGest and EDTA  
The dried thrombomodulin containing HPLC fractions were dissolved in 100 µL of 0.2% 
RapiGest in 50mM Bis-Tris, 4 mM EDTA, pH 6.0 buffer. The sample was sonicated for 1 hour. 
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Sufficient 0.35 M TCEP was added to make the final TCEP concentration of 20 mM. The sample 
was incubated at 60 °C for 30 minutes. 100 units of PNGaseF was added and incubated at 37 °C 
for 4 hours. 5 µL of fresh sequencing grade chymotrypsin (1µg/µL) was added and the sample 
was incubated for 12 hours at room temperature. The supernatant was removed and injected into 
the HPLC. The reaction was quenched and RapiGest decomposed with addition of TFA to final 
concentration of 25% TFA. The sample was injected into the HPLC.  
 
Quantification of methionine oxidation  
Alkylation of cysteine by fluorescent reagent 
The alkylation of cysteine by fluorescent reagent to thrombomodulin isolated from urine 
was performed for identification and quantification of our peptide. The three potential 
advantages of alkylation are increased sensitivity, fewer peaks detected by the fluorescent 
detector and, finally, alkylation prevents disulfide bond reformation. Synthetic peptide, 
APIPHEPHRCQMF, was alkylated with 5-((((2-iodoacetyl)amino)ethyl)amino)naphthalene-1-
sulfonic acid (1,5-IAEDANS)[150, 151]. 1, 5-IAEDANS has excitation wavelength of 336 nm 
and an emission wavelength of 490 nm.  
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Figure 2.1: Chemical structure of 1, 5-IAEDANS, molar mass is 434.25 g, excitation wavelength 
is 340 nm, and emission wavelength is 460 nm [152, 153].  
  
The 2 uL of 10 mg/mL synthetic peptide stock solution was dissolved in 198 µL 0.1 M 
Tris pH 8.0 that had 50 mM tris-carboxyethylphosphine (TCEP). The sample was incubated for 
10 minutes at room temperature. Next, 5 fold molar excess of 1,5-IAEDANS over total thiols 
was added. The samples were incubated for 8 hrs. 10 fold molar excess of 2-mercaptoethanol (2-
ME) over 1,5-IAEDANS was added to the sample after alkylation [154].  The sample was 
injected into the Waters ACQUITY UPLC System, BEH 130 C18 1.7 µm 2.1x150 mm column 
that was heated to 45°C, 0.4 mL/min flow rate. The PDA detector monitored at 214nm and 
fluorescence (FLR) detector excitation wavelength was 340 nm, and emission was monitored at 
460 nm). The initial solvent composition 10% MeCN/0.1% TFA, and it was transitioned to 20% 
MeCN/0.1% TFA in a convex curve gradient over two minutes.  Over the next 2.5 minutes, a 
linear gradient from 20% MeCN/0.1% TFA to 42% MeCN/0.1% TFA was run.  
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Determination of methionine 388 oxidation ratio by UPLC 
Following chymotrypsin digestion, the thrombomodulin fragments were injected into a 
Waters Acquity UPLC System with the detector monitoring 214 nm. The BEH 130 C18 1.7 µm 
2.1x150 mm reverse phase column was heated to 45 °C and a 0.2 mL/min flow rate was used to 
separate the peptide mixture. The eluent was started at 10% MeCN/0.1% TFA and transitioned to 
20% MeCN/0.1% TFA over two minutes.  Over the next 2.5 minutes, a linear gradient from 20% 
MeCN/0.1% TFA to 42% MeCN/0.1% TFA was run. The methionine and methionine sulfoxide 
forms of the peptide APIPHEPHRCQMF eluted at 11.5 and 22.2 minutes, respectively.  The 
peptide APIPHEPHRCQMF (synthesized by SIGMA Genosys) in the methionine and/or 
methionine sulfoxide forms was co-injected to confirm peak position.  After the run, the column 
was cleaned with 0.20 mL/min of 90% MeCN/0.1% TFA for 8 minutes followed by 5 minutes 
equilibration to 0.2 mL/min of 10% MeCN/0.1% TFA.  
Mass spectrometry analysis of methionine 388 oxidation 
The presence of oxidized and reduced forms of peptide in the chymotrypsin digested 
thrombomodulin was confirmed by matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry. The MALDI analysis was performed by the Statewide Mass Spectrometry Facility 
located at the University of Arkansas. The pure samples were mixed with the MALDI matrix, 2, 
5-dihydroxybenzoic acid (DHB) (Sigma Aldrich).  MALDI-TOF mass spectra were obtained on 
a Bruker Ultraflex II (Bruker Daltonic GMBH, Bremen, Germany) time-of-flight mass 
spectrometer operated in the positive-ion reflectron mode.  The accelerating voltage, delayed 
extraction time, and laser power were adjusted to optimize sensitivity and resolution for ions 
between m/z 500 – 4000. 
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Recombinant TMEGF 456 
To conduct a study of the oxidation of methionine in the thrombomodulin of smokers and 
non-smokers we were successful in purifying thrombomodulin from urine, however the 
quantities were not sufficient to study the oxidation occurring during individual steps and effects 
of additives to minimize oxidation occurring during the processing. Methionine 388 is found 
between EGF 4 and 5 of thrombomodulin, and this region is sufficient to activate protein C. 
Recombinant fragment EGF 456 of thrombomodulin was expressed using Pichia Pastoris to 
produce large quantity of recombinant protein. Fragments of human thrombomodulin were 
expressed in the Pichia pastoris expression system.  The construction of the P. pastoris 
expression system containing the gene TMEGF456 has been described by White et al. [62] and 
the expression system was the kind gift of Dr. Komives. The recombinant protein was produced 
using P. pastoris strain SMD1168, as this strain lacks protease A.  As a result of deficiency of 
protease A, this strain is deficient in carboxypeptidase Y and protease B1. Due to absence of 
proteases in this strain, the yield is typically much higher. The transformants of this strain can 
grow on the histidine deficient medium, since it is defective in dehydrogenase gene (his 4), this 
makes selection of transformants easier. The plasmid vector pPIC9K was used for insertion of 
synthetic gene for TMEGF456. Along with Met 388, the TMEGF456 fragment expressed in P. 
pastoris contains His and Met residues at the N-terminus. 
P. pastoris strains were typically grown on YPD-agar plates (2% (w/v) dextrose, 2% 
(w/v) peptone, 1% (w/v) yeast extract, and 2% (w/v) agar) or YPD medium (1% (w/v) yeast 
extract, 2% (w/v) dextrose, and 2% (w/v) peptone,). Single colony was selected from YPD-agar 
plate, and it was inoculated to a sterile flask which contained 10mL solution of YPD. This 
culture was placed in a shaker (300 rpm) for 24h at 30 ºC. The YPD solution was centrifuged for 
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10 min at 3000 rpm using Sorvall GS-3 rotor. The cells were collected and resuspended in YPD 
solution containing 15% glycerol, and aliquots of 1 mL were placed in sterile 1.5 eppendorf 
tubes. The tubes were flash frozen using liquid nitrogen and stored at -80 ºC, these ‘stocks’ were 
used to inoculate the fresh cultures. The selection of a single colony, inoculation of YPD 
solution, and preparation of storage of ‘stocks’ was done by Dr. Jeffery Froude, a former 
graduate student from our lab.     
 4 L of BMGY media was prepared. The BMGY media had composition of 1% (w/v) 
ammonium sulfate, 1% (w/v) casamino acids, 3.4 g/L yeast nitrogen base (without ammonium 
sulfate and amino acids), 2 mL/L biotin solution, 2% (v/v) 1 M potassium phosphate buffer pH 
6.0 and 1% (v/v) glycerol. The BMGY solution was sterilized by passing though the 0.2 µm 
bottle top filter. The 0.2 g/L of stock solution of biotin was prepared by dissolving in 0.02 M 
potassium hydroxide solution, and passing it through 0.2 µm PES filter, and were stored in -20 
ºC. 2 L culture flasks were covered with four layers of cheese cloth and two layers of aluminum 
foil, and were autoclaved for 30 min at 121 ºC. Approximately 320 mL of sterilized BMGY 
media were aseptically transferred to the 2 L sterile flasks.  
 A sterile 150 mL baffled flask was used to prepare the starter culture of P. pastoris. 10 
mL of sterile BMGY media and 2 mL of frozen stock culture was added to the flask, and was 
placed in a shaker (3000 rpm) at 30 ºC for 12 hrs. 1mL of starter culture was added to the 2 L 
culture flasks containing BMGY media. After 24 hrs of growth, the aluminum foil was removed 
from the culture flasks, cheese cloth was not removed, and was continued to incubate for 
additional 24 hrs. Following 2 days of incubation, the culture was transferred to 400 mL 
centrifuge bottles and centrifuged at 2500 rpm for 10 min using Sorvall GS-3 rotor. The 
supernatant was discarded, and the cell pellets were redissolved in BMMY media. BMMY media 
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composition is identical to BMGY, except 2 % methanol is used instead of 1 % glycerol. The 
BMMY suspended cells were placed in the culture flask and covered with four layers of 
cheesecloth. The flasks were incubated in the shaker (300 rpm, 30 ºC) for 36 hrs. Upon 
completion of the induction phase, the culture was centrifuged at 3000 rpm for 45 min. The 
supernatant was collected and disodium EDTA was added to make the final concentration 5 mM. 
The supernatant was passed through the 0.22 µm bottle top filter to remove the particulates. A 
prefilter was used along with the bottle top filter to prevent the premature clogging of the 0.2 µm 
filter.  
The purification of the supernatant was based on anion exchange chromatography using 
Q-sepharose FF. The pH of the supernatant was adjusted to 6.5 by addition of sodium hydroxide. 
This step is crucial for the TMEGF456 to bind to the anion exchange column. Two buffers were 
prepared for the ion exchange, buffer A (50 mM Tris, 1 mM EDTA) and buffer B (50 mM Tris, 
1M NaCl, and 1 mM EDTA).  The anion exchange column was prepared by packing q-sepharose 
FF into an empty 200 mL glass column. 40 mL bed volume of q-sepharose ff was loaded into the 
glass column. The column was attached to the FMI pump attached with solvent inline filter. The 
column was equilibrated with 5 bed volumes of buffer A. The flow rate was set to 5 mL/min. 
Following equilibration the filtered supernatant was passed through the column at the rate of 
5mL/min. Since this part of the procedure took several hours to complete, the ion exchange was 
performed in the cold room at 4 ºC. The column was washed with 3 column volumes of buffer A. 
The TMEGF456 was eluted by step gradient with buffer B through the column. The proteins 
eluted after the gradient was changed to 30% buffer B. The fractions containing TMEGF456 
were verified using protein C activation assay.  The active fragments were concentrated down to 
2 mL volume using Centricon plus-70 centrifugal filter units with 10 kDa molecular weight 
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cutoff (Millipore). The concentrated fractions were injected into a reverse phase Waters HPLC 
system. The HPLC system contained Vydac dC18, 5 μm particle, 300 Å 4.6x250 mm column 
held at 58 °C. Upon injection, a gradient is run at flow rate of 1 mL/min from 10 to 26% 
acetonitrile, 0.1 % trifluroacetic acid over 8 minutes, followed by 26% to 40% acetonitrile over 
the next 14 minutes and finally from 40% to 90% over the next 25 minutes.  
 
Results and Discussion:  
Purification of thrombomodulin   
Thrombomodulin is anchored on the luminal surface of the endothelium and as 
previously indicated, thrombomodulin lacking the cytoplasmic domain appeared normal. 
Thrombomodulin undergoes endocytosis and degradation, and a significant amount of it is 
cleaved off and it is found in blood. The concentration of thrombomodulin in serum and plasma 
are reported to be between 3 to 300 ng/mL [84]. The thrombomodulin is removed through urine.  
Several groups have previously developed methods to isolate thrombomodulin from urine. The 
methods they developed were not intended for repeated and rapid purification of 
thrombomodulin from urine. They also used large volumes of pooled urine sample to isolate 
thrombomodulin, for example, Jackson et al, started from 38 L of urine to isolate 
thrombomodulin. The previously developed methods were not applicable for our study, since we 
needed quick method of thrombomodulin isolation from urine. The need for rapid processing 
stems for our need to prevent oxidation occurring during processing and also to compare levels 
of oxidation occurring in different individuals.     
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Thrombomodulin concentration in urine was assayed by using IMUBIND 
Thrombomodulin ELISA kit by American Diagnostica Inc. This is a sandwich ELISA which 
employs two monoclonal antibodies, first antibody recognizes the EGF1-EGF2 region of 
thrombomodulin, and second antibody recognizes EGF5-EGF6 region. At the end of the assay, 
the concentrations of thrombomodulin were determined by measuring the solution absorbance at 
450 nm using a Safire microplate reader by Tecan. Typical volume of morning urine obtained 
from a donor was 200-500 mL. The urine from the morning was chosen since they have more 
volume, and they are higher concentration of thrombomodulin. The average concentration of 
thrombomodulin in urine before any processing was 3-8 ng/ml, based on ELISA assay.  
 As mentioned in the materials and methods section, several methods were tested for purification 
of thrombomodulin from urine prior to purification using HPLC. Regardless of the method, after 
collection, urine samples were cooled in 4 °C for no more than 2 hours, and centrifuged in 
Sorvall GS-3 rotor at 4,000 rpm for 30 min at 4 °C. The samples were stored at 4 °C because the 
cooling produces precipitate.     
Tangential flow filtration (TFF) System 
   Labscale Tangential Flow Filtration (TFF) System, manufactured by Millipore, was 
tested for the concentration of the urine sample. In regular filtration, particles that are too big to 
pass through the membrane are retained on the membrane surface, and small particles pass 
through the membrane. As the filtration progresses, the large particles accumulate on the surface 
of the membrane, this lowers the surface area of the membrane, and small particles do not pass 
through the membrane. In TFF system, solution is pumped tangentially along the surface of the 
membrane, unlike normal filtration where the flow of the solution is normal to the plane of the 
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membrane. The applied pressure forces the smaller molecules through the filter and the 
molecules that are too big to pass through the membrane are swept away by the tangential flow.    
Jumbosep spin filter 
Jumbosep spin filters were tested for the concentration of the urine sample. The 
Jumbosep centrifugal device (Pall) consists of sample reservoir, membrane filter insert, and the 
filtrate receiver. The membrane filters are constructed from modified polyethersulfone on 
polyethylene substrate, and they are low protein binding. A membrane filter with molecular 
weight cut off of 30 kd was used for purification. The urine sample that was previously cooled at 
4 °C was concentrated followed by buffer exchange, passed through SP Sepharose FF and Q 
Sepharose FF, and thrombomodulin was eluted. We compared the amount of thrombomodulin 
retained in the concentrate after the purification using Jumbosep and TFF system. The urine 
sample was split into two equal parts and they were run simultaneously. The ELSIA test showed 
that there was ten times higher concentration of thrombomodulin in retentate from Jumbosep 
compared to TFF system. We did not incorporate the concentration step in our final purification 
method, however if we incorporate a concentration step in the future, we will use Jumbosep.   
Q sepharose  purification  
The urine sample that was cooled at 4 °C and centrifuged in Sorvall GS-3 was passed 
through the polyethersulfone 0.2 µm bottle top vacuum filter from corning. These hydrophilic 
filters are low binding to proteins and they remove particulates during filtration. The removal of 
particulates is necessary prior to the downstream ion exchange; their presence will clog the Q 
Sepharose column and lower the column life. Ideally, buffer exchange would be an appropriate 
step for the urine sample to undergo so the ionic strength of the various samples is constant. 
42 
 
Buffer exchange with high volumes of samples would be time consuming; instead 0.25 M 
imidazole acetate at pH 6.0 was added to make final concentration 25 mM imidazole acetate. 
Thrombomodulin is a very acidic protein; the pI of the protein is approximately 4.8. The pH of 
the urine sample was adjusted to 6.0 to make the protein negatively charged. Next, the urine 
sample was passed through a 50 mL Bio-Rad column containing 20 mL bed volume of Q 
Sepharose FF using FMI pump. The column was previously equilibrated with 3 bed volumes of 
25 mM imidazole acetate at pH 6.0. The negatively charged proteins along with thrombomodulin 
bind to the ion exchange column. As previously mentioned, thrombomodulin is not found intact 
in urine, instead it is fragmented. Fortunately, all the thrombomodulin fragments are uniformly 
acidic throughout its length, making the ion exchange purification of its various fragments 
simple. The column is washed with 25 mM imidazole acetate at pH 6.0, and proteins are eluted 
using 25 mM imidazole acetate, 50 mM NaCl at pH 6.0, and 25 mM imidazole acetate, 0.5 M 
NaCl at pH 6.0. Eluents following the addition of 25 mM imidazole acetate buffer, pH 6.0, 0.5 M 
NaCl was collected in 15 mL conical tube, 5 mL in each tube. 15 mL eluent, after addition of 25 
mL of 25 mM imidazole acetate buffer, pH 6.0, 0.5 M NaCl, tested positive for thrombomodulin. 
Solution of 0.2 M L-methionine was added to thrombomodulin containing fractions to make final 
concentration 2 mM methionine. Methionine was added as a sacrificial molecule to absorb 
oxidants that might be occurring during the downstream processing. The thrombomodulin 
containing fractions dried using medium heat, under vacuum, using the SpeedVac concentrator 
system. The SpeedVac surface that was accessible to light was covered with aluminum foil to 
prevent photooxidation. The dried samples were reconstituted into 18.2 megaohm pure water.       
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 Reverse phase HPLC purification  
Thrombomodulin containing fragments from Q Sepharose were dried using SpeedVac 
under vacuum, and reconstituted in 18.2 megaohm pure water, passed though the 0.2 µM spin 
filter, and were injected into the HPLC. A shows the HPLC chromatogram obtained from the 
injection of 1.4 mL sample of 27 year old male donor. Figure 2.2 B is the magnification of 
Figure 2.2 A, and it spans the area where thrombomodulin elutes, namely at 30 minute. The total 
amount of thrombomodulin isolated from a single urine sample after the HPLC purification was 
0.05–0.1 µg, which is not sufficient to compare the relative oxidation of methionine 388 
oxidation. Multiple urine samples were collected from an individual donor to increase the 
amount thrombomodulin collected following HPLC purification. Typically 2-3 urine samples 
were collected from a donor within consecutive days, 0.15-0.25 µg thrombomodulin was 
collected after the samples were pooled.  
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B. 
 
 
Figure 2.2 A&B: Final purification of thrombomodulin by reverse phase HPLC.  The following 
sample, a final purification of a male non-smoker urinary thrombomodulin, contained 
thrombomodulin in the peak at 30 minute. Figure 2.2 B is a selected area from Figure 2.2 A.  
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Oxidation during processing 
Oxidation that could be occurring during the purification of thrombomodulin has always 
been a concern. Several steps were taken to minimize the oxidation that was occurring during 
processing. During the lyophilization step, the samples were shielded from light to prevent photo 
oxidation of methionine. The transparent regions of the speedvac were covered with aluminum 
foil. Thiodiglycol was added to the urine samples prior to collection. It was added as a scavenger 
molecule to prevent methionine oxidation. 5 mL of thiodiglycol was added to the centrifuge 
bottle before the samples were collected. 1 mL of 0.5 M EDTA pH 8.0 was added to the 
centrifuge bottles prior to urine collection. EDTA is a chelator[155], and it has been shown to 
slow Fenton oxidation[156, 157]. Following the elution of thrombomodulin from the Q-
sepharose FF column and reverse phase HPLC, free methionine was added to make the final 
concentration to 2 mM. This was added as sacrificial molecule to prevent oxidation of 
methionine 388 during processing.     
Final method for the purification of thrombomodulin 
 The urine sample was cooled at 4 °C, centrifuged in Sorvall GS-3, and passed through the 
polyethersulfone 0.2 µm bottle top vacuum filter. The pH of the sample was adjusted to 6.0, and 
the sample was passed through a column containing 20 mL bed volume of Q Sepharose FF. The 
protein was eluted using NaCl gradient, and dried under vacuum, and injected into the reverse 
phase HPLC. There was ten times the amount of thrombomodulin retained after the purification 
using Jumbosep compared to TFF system. The purification using 20 mL bed volume of Q 
Sepharose FF purified 1.5 fold more thrombomodulin compared to Jumbosep, however Q 
Sepharose FF was without any preconcentration step. Besides the low yield of thrombomodulin, 
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the concentration using Jumbosep or TFF was also accompanied by other drawbacks. The 
purification and buffer exchange of 400 mL of urine sample required on average 6 hours, which 
increased the likelihood of our protein being oxidized. Also, it required frequent buffer changes 
and manipulation of the sample, so was quite labor intensive. On the other hand, the processing 
time using Q Sepharose FF typically was just 2-3 hours and, equally importantly, gave a higher 
yield of thrombomodulin.    
 
Digestion of thrombomodulin 
The linear chains of amino acids fold into a specific structure to carry out their functions. 
The folded protein in its native state is stable under physiological conditions. The forces behind 
the 3D folded structure of proteins are following: 1) Hydrogen bonds [158]. 2) Van der Waals 
interactions. 3) Backbone angle preferences. 4) Electrostatic interactions. 5) Hydrophobic 
interactions [159-161]. Collectively these forces can be referred to as forcefields [162]. In order 
for a protein to undergo complete digestion, the forcefield associated with the folded protein 
must be disrupted to unfold the protein. The folded protein imposes steric hindrance to the 
protease, as a result the protease is unable to access and ultimately cleave the protein. In most 
proteomics studies it is assumed that the digestion of proteins is driven to completion, and such 
assumption is correct for most proteins. However, many proteins are resistant to proteolysis, and 
they do not undergo complete digestion. There are several factors that affect the protein 
digestion, including but not limited to ineffective denaturation due to poor protein solvation, lack 
of localization of enzyme, short reaction time, and the competing presence of other proteins in 
the digestion [163]. Effective digestion of purified thrombomodulin was crucial to quantify the 
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reduced and the oxidized peptides ratios to quantify the methionine oxidation. We monitored the 
degree of thrombomodulin digestion by chymotrypsin by injecting the digested sample into the 
HPLC. The degree of digestion was calculated by comparing the area of the peak occupied by 
thrombomodulin in HPLC chromatogram before and after chymotrypsin digestion (Figure 2.3).  
Digestion using manufacturer’s protocol 
Using the manufacturer’s protocol in which the HPLC purified dried thrombomodulin 
fraction was reconstituted in minimal volume of 200 mM Tris-HCl pH 8.0, reduced using TCEP, 
deglycosylated, and digested for 2 hrs using 4 Units of chymotrypsin dissolved in 50 mM Tris-
HCl, 1mM CaCl2, pH 8.0 only digested 15 % of the total thrombomodulin. Until this point, we 
were under the assumption that the digestion using chymotrypsin went to completion, hence we 
focused towards creating a method in the Acquity UPLC that would provide a PDA 
chromatogram that gave us resolved oxidized and the reduced peaks following digestion of 
thrombomodulin. Little did we know, only 15% of the thrombomodulin underwent complete 
digestion after 2 hr reaction with chymotrypsin (Figure 2.3). Following this discovery, the 
priority for this project was to create a digestion method that would effectively digest 
thrombomodulin to the extent that would allow us to detect the oxidized and the reduced forms 
of peptide using the quantification of methionine techniques that will be discussed further in this 
chapter.  
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Figure 2.3 A&B: HPLC chromatogram of purified thrombomodulin prior to chymotrypsin 
digestion (A). HPLC chromatogram of 2 hr chymotrypsin digested thrombomodulin (B). Two 
chromatograms were used to monitor the extent of digestion. The efficiency of various digestion 
protocols were tested using this method.  
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Digestion using urea  
Protein digestion using urea is still the most widely used technique to solubilize proteins 
in a solution digestion. The mechanism of protein denaturation by urea is believed to begin with 
attachments of urea to histidine, and then to the amide groups and positively charged amino acid 
and, which results in disruption of the hydrogen bonds, followed by water and urea solvation 
[164, 165]. Over the time, urea in water releases isocynate, which can carbamylate primary 
amines, hence urea was freshly prepared. Also, upon heating, urea can degrade into ammonium 
cyanate, which can lead to the carbamylation of the primary amines. Based on the 
manufacturer’s manual, chymotrypsin retains 100% enzymatic activity in up to 4M urea. In the 
experiments where 8M urea was used, the concentration of the urea was halved by dilution using 
the appropriate buffer prior to addition of chymotrypsin. The thrombomodulin digestion using 
2.5 M and 8 M urea did not enhance the digestion compared to the initial method.  
Digestion using acetonitrile 
Changing the solvent in which the digestion is probably the most convenient way to 
facilitate the solubilization of the protein, and increased solubility can potentially increase the 
rate of digestion by protease. Trypsin digestion of protein in acetonitrile has been used in some 
proteomics studies [166, 167]. Trypsin digestion was conducted on myoglobin and chicken 
ovalbumin using organic solvent [167]. These proteins are resistant to proteolysis unless they are 
subjected to thermal or chemical denaturation prior to digestion. These proteins are easily 
digested in organic solvent, efficient digestion occurred within 5 min [167]. The autolysis of the 
protease is a concern when using organic solvents, but the proteolytic activity of trypsin is not 
affected even in 80% acetonitrile solution. Also, since these protocols did not use chaotropes or 
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surfactants, it makes downstream MS or HPLC analysis easier. The use of chymotrypsin to 
digest thrombomodulin in an organic solvent was attempted achieve complete digestion. 
Chymotrypsin in water miscible organic solvents like methanol, ethanol, 1-propanol, 2-propanol 
and acetonitrile shows enhanced stability and catalytic activity [168]. In the presence of 20% 
acetonitrile in buffer, the enzyme activity of chymotrypsin increased up to 6 fold. Accordingly, 
thrombomodulin was dissolved in acetonitrile in 50 mM Tris-HCl/10 mM CaCl2, pH 8.0 buffer. 
Multiple experiments where the concentration range of acetonitrile was varied between 20%-
50% were conducted. Unfortunately, this method did not enhance the digestion compared to the 
initial method.  
Digestion using Invitrosol 
Invitrosol is a proprietary surfactant from Invitrogen. It keeps hydrophobic proteins in the 
solution and it has no effect on the activity of protease. More importantly, it is compatible with 
HPLC and MS analysis, unlike most surfactants that interfere with such instruments. The use of 
Invitrosol to enhance the digestion of thrombomodulin from urine did not result in significant 
improvement in digestion. Experiments using organic solvent along with Invitrosol did not 
enhance the digestion compared to the initial method.  
Digestion using RapiGest  
RapiGest SF is an acid labile surfactant. It can be immediately be degraded from solution 
by addition of acid. It decomposes into dodeca-2-one and sodium-3-(2,3-dihydropropoxy) 
propanesulfonate. The first product is insoluble in water and second is highly soluble in water, so 
it is not retained in reverse phase HPLC. This feature makes the use of this surfactant attractive, 
since it does not interfere with the downstream analysis like HPLC and MS.  RapiGest SF 
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improves solubility of protein in a solution and is an enzyme friendly surfactant for in-solution 
protein digestion. Proteases are resistant to denaturation in RapiGest SF solution. Trypsin has 
100% activity in 0.1% RapiGest SF solution, and 87% activity in 0.5% RapiGest solution[169]. 
The proteins unfold in RapiGest SF solution and the proteolytic sites are exposed for digestion. 
The globular proteins, which are typically difficult to digest, can be digested within minutes 
using RapiGest SF [170]. This surfactant also aids in deglycosylation of proteins. However, the 
use of RapiGest SF to digest the thrombomodulin isolated from urine did not enhance the 
digestion compared to the initial method.  
Digestion using EDTA      
The thrombomodulin EGF domains 5 and 6 are the primary binding site for thrombin 
[171, 172], while EGF4 of thrombomodulin is necessary for the thrombin-thrombomodulin 
mediated protein C activation [173, 174]. In studies using recombinant thrombomodulin, the 
thrombin-thrombomodulin mediated activation of protein C shows a bell shaped dependence on 
Ca
2+ 
concentration. Ca
2+
 binds to EGF3 and EGF6 region of thrombomodulin, the binding 
affinity is almost 15 fold higher in the EGF6 region based on Ca
2+
 analysis of dialyzed 
recombinant thrombomodulin [175]. There is a higher proportion of β-sheet and more structured 
conformation seen in the EGF domains that are saturated with Ca
2+
. The ordered conformation 
resulted in decreased efficiency of trypsin to cleave the C-loop of EGF6. We alternatively 
hypothesized the partial digestion of thrombomodulin might be due to Ca
2+
 stabilization.  
Proteins can be converted into apoproteins by addition of chelators like EDTA and 
EGTA. Ca
2+
 binds to thrombomodulin EGF3 and EGF6, and the binding of Ca
2+ 
results in 
formation of secondary structures in these regions. The stabilization induced by Ca
2+
 binding is 
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known to make thrombomodulin resistant to protease digestion [175]. The simple method to 
expedite the digestion of thrombomodulin might be by removal of Ca
2+
. Thrombomodulin 
purified from urine was digested using chymotrypsin in presence of 10 mM EDTA. Upon 
completion of digestion, the digested sample was injected into reverse phase HPLC to assess the 
degree of digestion. The HPLC peaks corresponding to thrombomodulin were no longer seen in 
the chromatogram, indicating complete digestion of thrombomodulin. Sample of digested 
thrombomodulin in presence of EDTA was sent for MS analysis. The MS did not identify 
peptides corresponding to 1562 or 1578 m/z. The results were puzzling, HPLC indicated the 
digestion had gone to completion; however MS did not confirm the presence of the methionine 
388 containing peptide. The experiment were repeated several times, however the results 
consistently remained the same. The results were puzzling until we found the following paper, 
“The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2” [176].  
Zinc-binding proteins comprise one of the largest classes of protein and they are very important 
for the gene expression. This class of protein includes transcription factors of the DNA, co-
activators, RNA polymerase and chromatin-modifying and -remodeling enzymes [177]. Many 
zinc-binding proteins need Zn
2+
 to fold into their 3D structure, and for participation in their 
intermolecular interactions. In the mentioned study [176], the zinc domain of transcriptional 
proteins CBP (CREB-binding protein) and p300 were studied. The zinc binding domain when 
treated with EDTA resulted in denaturation of the protein. They attempted to restore the native 
structure of the protein by addition of excess Zn
2+
  following EDTA denaturation, this did not 
result in refolding of the protein, suggesting irreversible denaturation by EDTA. More 
significantly, their results showed that under EDTA induced denaturation the proteins formed 
non specific interactions resulting in aggregation of proteins. They concluded that the EDTA 
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mediated denaturation leads to irreversible denaturation and aggregation of the proteins. Based 
on these findings, we believe that EDTA induced denaturation and aggregation resulted in 
disappearance of thrombomodulin peak in the HPLC chromatogram. The pursuit of 
thrombomodulin digestion using EDTA was discontinued.   
Final method for the digestion of thrombomodulin 
The dried thrombomodulin containing fractions from the reverse phase chromatography 
were pooled and dissolved in approximately 100 uL of 1X phosphate buffered saline (PBS).  The 
samples that were cloudy prior to digestion were spun in a microcentrifuge (Galaxy 14D VWR) 
at 13K RPM for a minute. This undissolved material proved to contain the bulk of the 
thrombomodulin.  Fortunately, after the supernatant was removed, the precipitate readily 
dissolved in 75 µL of 1X PBS. Fresh tris-carboxyethylphosphine (TCEP) was added to make the 
final concentration of 50 mM TCEP. 10 µL of 0.5 M sodium phosphate buffer pH 7.5 added to 
the sample, prior to addition of 500 units of PNGase F (New England Biolabs). The samples 
were incubated at 37°C for 4 hours to deglycosylate the sample. The protein was then digested at 
30°C for 8 hours after adding 4.1 μg of sequencing grade chymotrypsin (Princeton Separations) 
dissolved in 50 mM Tris-HCl, 1mM CaCl2, pH 8.0. The chymotrypsin was inactivated by 
placing the samples in a 100°C dry bath for 30 seconds. This method achieved thrombomodulin 
digestion which resulted in detection of both reduced and oxidized peptides by MALDI-TOF. 
This method was incorporated into the final purification and qualitative analysis of 
thrombomodulin.   
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Quantification of methionine oxidation  
The quantification of urinary thrombomodulin methionine 388 oxidation involves 3 three 
major steps: 1) purification of thrombomodulin from urine, 2) digestion of purified 
thrombomodulin 3) quantification of methionine oxidation. We have discussed the first two 
steps, in this section we will discuss the methods attempted to complete the final step.   
Alkylation of cysteine by fluorescent reagent 
Cysteine is the most reactive residue commonly found in proteins and peptides.  In its 
unprotonated state, the thiol group is strong nucleophile and will react with a wide variety of 
reagents.  The alkylation of cysteine side chain was attempted for two reasons. First, the 
alkylation of cysteine prevents reformation of disulfide bonds which subsequently prevents the 
formation of the secondary structure hence protein remains in the denatured state. And second, 
our hope was to introduce a fluorescent reporter group on the peptide APIPHEPHRCQMF. 
Several peptides are formed when thrombomodulin is digested by chymotrypsin, not all of these 
peptides have cysteine. Only the peptides that have cysteine will have the covalently bonded 
fluorescent reporter group, when the digested and alkylated sample is injected into an HPLC 
with fluorescent detector, only the fluorophores will be detected by the detector. The attachment 
of fluorophore eliminates the noise from non fluorophore peptides, and in theory would increase 
the resolution and sensitivity of detection of the oxidized and the reduced peptide.   
Reaction of the sulfhydryl group of cysteine with α-haloacids or their amide derivatives is 
the most common method used to alkylate cysteine. The iodo compounds is preferred over other 
halides since iodide is a much better leaving group, hence the reaction is much faster. 5-((((2-
iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid (1,5-IAEDANS) [150] was used for 
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alkylation of cysteine in thrombomodulin. Reaction of a cysteine side chain with 1, 5 IEADANS 
produces dansylated cysteine on the protein (Figure 2.4). 1, 5-IAEDANS has a peak excitation 
wavelength of 336 nm and a peak emission wavelength of 490 nm. The extinction coefficient of 
the dye is 5700.  
 
Figure 2.4: Alkylation of cysteine using 1, 5-IAEDANS.  
   
Before attempting to alkylate the cysteine residues in thrombomodulin, the alkylation 
using 1, 5-IAEDANS was attempted in the synthetic peptide APIPHEPHRCQMF.  The 2 µL of 
10 mg/mL synthetic peptide stock solution was dissolved in 198 µL 0.1 M Tris-Cl pH 8.0 
containing 50 mM freshly prepared tris-carboxyethylphosphine (TCEP). The sample was 
incubated, and 5 fold molar excess (over total thiols) of freshly prepared 1, 5-IAEDANS was 
added. Nitrogen was flushed over the surface of the liquid and the microcentrifuge tube was 
sealed. The sample was incubated for > 4 hrs at 37 °C. Following alkylation, 10 fold molar 
excess of 2-mercaptoethanol (2-ME) over 1,5-IAEDANS was added to the sample [154]. The 
sample was injected into the Waters ACQUITY UPLC System, BEH 130 C18 1.7 µm 2.1x150 
mm column, and Fluorescence (FLR) detector (excitation wavelength 340 nm, and emission 
wavelength 490 nm). The methionine and methionine sulfoxide forms of the peptide 
APIPHEPHRCQMF eluted at 2.25 and 2.5 minutes, respectively. The alkylated oxidized and 
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reduced peptides eluted at 2.35 and 2.6 minutes, respectively. Figure 2.5 is a UPLC 
chromatogram of 4 µL injection of 0.1 µg/µL synthetic peptide alkylated using 1, 5-IAEDANS 
for 16 hrs at 37 °C, and Figure 2.6 is UPLC FLR chromatogram of the same injection.    
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Figure 2.5: Acquity UPLC chromatogram of IAEDANS labeled synthetic APIPHEPHRCQMF 
and APIPHEPHRCQMoxF at 214nm. Two forms of non alkylated peptide APIPHEPHRCQMF 
eluted at 2.25 and 2.5 minutes, respectively. The alkylated oxidized and reduced peptides eluted 
at 2.35 and 2.6 minutes, respectively.  
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Figure 2.6: UPLC FLR chromatogram of IAEDANS labeled synthetic peptide 
APIPHEPHRCQMoxF and APIPHEPHRCQMF. The two peptides eluted at 2.35 and 2.6 
minutes, respectively. 
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The cysteine alkylation by 1,5-IAEDANS was attempted on urinary thrombomodulin 
purified by HPLC. The protocol used to alkylate the synthetic peptide was used to alkylate the 
purified thrombomodulin. The alkylated thrombomodulin was digested using chymotrypsin, and 
subsequently injected into the Acquity UPLC. Based on alkylation experiments performed using 
the synthetic peptide, the elution time of the alkylated oxidized and the reduced peptide was 
discovered. The FLR detector did not detect alkylated oxidized and the reduced peptide 
following alkylation using 1,5-IAEDANS and digestion using chymotrypsin. We hypothesized 
the absence of the alkylated peptides in FLR chromatogram resulted from ineffective alkylation, 
which was mostly likely due to stubbornness of thrombomodulin to denature. This method was 
not incorporated in quantification of methionine 388 oxidation, because significant alkylation of 
thrombomodulin could not be achieved that would produce alkylated peptide FLR signal.  In 
retrospect, the difficulty may have been the lack of digestion of thrombomodulin, so revisiting 
this labeling procedure may be worthwhile.        
Determination of methionine 388 oxidation by UPLC 
Acquity UPLC offers increased resolution, sensitivity and speed compared to HPLC. It 
uses small particle columns (1.7 µm – 1.8 µm), which improves system efficiency by producing 
better resolution, and also lowering the analysis time. This system is designed to minimize band 
spreading resulting from the column and also from the instrument. Several UPLC methods were 
developed to separate the synthetic peptide mixture (APIPHEPHRCQMoxF and 
APIPHEPHRCQMF). New methods were created by changing the gradient, temperature, flow 
rate, and column. After numerous experiments we developed our most effective UPLC method 
for purification. Using this method the oxidized and the reduced peptides in the synthetic peptide 
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mixture eluted at 12 and 21 minute respectively, they were 9 minutes apart from each other         
( Figure 2.7).  
 
Figure 2.7: Acquity UPLC chromatogram of the commercial peptide mixture. 
APIPHEPHRCQM(ox)F elutes at 12 min and APIPHEPHRCQMF elutes at 21 min.  
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The ratio of oxidized and reduced peptide within the synthetic peptide can be calculated 
using the UPLC chromatogram simply by the dividing the area occupied by the oxidized by area 
occupied by the reduced peptide. Using this approach we should able to calculate the ratio of the 
reduced and the oxidized peptide in a chymotrypsin digested thrombomodulin sample. The ratio 
of reduced and the oxidized peptide within a sample is equivalent to the ratio of reduced and the 
oxidized methionine in a sample of thrombomodulin purified from urine.      
The HPLC purified dried thrombomodulin following chymotrypsin digestion using was 
injected in the UPLC. The elution of the oxidized and the reduced peptide was mapped using the 
synthetic peptides, they elute at 12 and 21 min respectively. Figure 2.8 is UPLC chromatogram 
of 25 µL injection of chymotrypsin digested thrombomodulin of 26 year old non smoker donor.   
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Figure 2.8: UPLC chromatogram of chymotrypsin digested urinary thrombomodulin of 26 year 
old non smoker donor.   
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Figure 2.9: Overlay of UPLC chromatograms. Top chromatogram is of chymotrypsin digested 
urinary thrombomodulin of a 26 year old Caucasian male non smoker, and the bottom 
chromatogram is of synthetic peptide mixture. 
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Figure 2.9 is overlay of UPLC PDA chromatogram of chymotrypsin digested urinary 
thrombomodulin and synthetic peptide mixture. As seen in the figure the oxidized and the 
reduced peaks of the chymotrypsin digested urinary thrombomodulin is not resolved, especially 
the oxidized peptide.  Much time and resources were devoted to develop methods to resolve the 
two peaks, however the resolution necessary to calculate the relative area occupied by the 
reduced and the oxidized peaks could not be achieved.   
 
Figure 2.10: MALDI-TOF spectra of chymotrypsin digested thrombomodulin purified from 
urine. The sample was collected from a 28 year old male smoker. The oxidized and the reduced 
forms of peptide are present in this sample.   
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Mass spectrometry analysis of methionine 388 oxidation 
Matrix-assisted laser desorption ionization (MALDI) is a powerful technique for mass 
spectrometry of peptides and proteins [178]. This technique provides fast and accurate 
acquisition of molecular mass and purity. The digested thrombomodulin was sent for MALDI 
analysis in Mass Spectrometry Facility located at the University of Arkansas. Figure 2.10 is 
MALDI-TOF spectra of chymotrypsin digested urinary thrombomodulin from a 28 year old male 
smoker. The isotopically averaged mass of reduced (APIPHEPHRCQMF) and oxidized 
(APIPHEPHRCQMoxF) peptides is 1562.73 and 1578.74 Da respectively. Both forms of 
peptides were detected by MALDI-TOF, and the intensity of the oxidized peptide was three fold 
more compared to its counterpart. This technique can be used for semi-quantitative test for the 
two forms of peptide.   
Final method for the quantification of methionine 388 oxidation 
 The chymotrypsin digested thrombomodulin alkylation using 1,5-IAEDANS did not 
result in sufficient alkylation of the peptides, and they could not be visualized in the FLR 
detector. Separation of reduced and the oxidized peptides using Acquity UPLC could not 
produce sufficient resolution to quantify the oxidation of methionine. The MALDI TOF injection 
of digested thrombomodulin confirmed the presence of two forms of peptides and also provided 
their relative intensities. This intensity of the peptides was used for the quantification of the 
methionine oxidation, the details of this method will be covered in the following chapter.     
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Conclusion  
In this chapter we have discussed techniques that were used to for 1) purification of 
thrombomodulin from urine, 2) digestion of purified thrombomodulin 3) quantification of 
methionine oxidation. The cooled urine sample centrifuged in a Sorvall GS-3 rotor, filtered using 
0.22 µm PES membrane filter, passed through Q Sepharose FF, and reverse phase HPLC 
provided maximum yield. The digestion of purified thrombomodulin where the samples were 
washed in 1XPBS buffer prior to addition of chymotrypsin was the most successful compared to 
other methods. The fluorophore and Acquity UPLC system could not be used for quantification 
of methionine oxidation. MALDI-TOF was used for quantification of methionine oxidation; this 
topic will be discussed in detail in chapter 3. This procedure works well, but it is worth 
considering how it might be improved in the future.   
Oxidation that might be occurring during the purification of thrombomodulin would not 
invalidate a finding that one population had a higher level of oxidation than another, but would 
complicate comparison of absolute levels of oxidation.  Based on oxidation experiments using 
synthetic peptide, we believe significant oxidation is not occurring during processing. A 300 uL 
of synthetic peptide APIPHEPHRCQMF was divided into three 100uL aliquots, the first aliquot 
was control. The second aliquot was dried under medium heat (45°C) for 4 hours in SpeedVac, 
and upon drying the synthetic peptide was reconstituted in distilled water to make the final 
volume 100 uL. The third 100 uL aliquot was allowed to sit in room temperature for 4 hours, 
which is the time samples are subjected to chymotrypsin digestion and which is also 
approximately the time it takes for a sample to be centrifuged and passed through the Q 
Sepharose FF column. All three samples were separately injected into the Acquity UPLC and the 
ratio of oxidized and the reduced form of APIPHEPHRCQMF for each sample was calculated. 
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The ratio of reduced and oxidized peptide remained constant in all three samples. The calculation 
was performed comparing the relative area occupied by reduced and oxidized peak in the UPLC 
PDA chromatogram at 214nm.  
Although this experiment was reassuring, steps were taken to minimize oxidation of 
protein during processing. During the lyophilization step, the samples were shielded from light to 
prevent photo oxidation of methionine. Thiodiglycol was added to the urine samples prior to 
collection. Thiodiglycol was added as a scavenger molecule to minimize methionine oxidation 
[179, 180]; it was added to the urine sample container before collection. EDTA was also added 
to the sample container prior to urine collection. EDTA is a chelator [155, 181], and it has been 
shown to slow Fenton oxidation [156, 157], and would also inactivate any metal dependent 
proteases that might be present[182, 183]. Following the elution of thrombomodulin from the Q-
sepharose FF column and reverse phase HPLC, free methionine was added as a sacrificial 
molecule to minimize oxidation. None of these additives used to minimize oxidation were used 
for the synthetic peptide oxidation experiments. Oxidation of synthetic peptide dissolved in 
water may not mimic the behavior of protein in urine, because latter is a complex solution 
composed of cells, proteins and salts.  However, the methionine in the synthetic peptide is fully 
exposed to the solvent, and methionine 388 in thrombomodulin is partly buried in the protein’s 
hydrophobic core, which might make it less susceptible to oxidation than the synthetic peptide.  
While we are reasonably confident that oxidation of the protein is not occurring, experimental 
proof of this would be useful. 
In the future, experiments can be designed to test the competency of each of the 
mentioned steps to minimize oxidation during processing. It is possible to produce large 
quantities of the recombinant TMEGF 456 using Pichia pastoris. As previously mentioned, 
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methionine 388 is found between EGF 4 and 5 of thrombomodulin. The recombinant TMEGF 
456 could be subjected to the urine purification protocol. Recombinant TMEGF 456 could be 
purified containing only single additives, followed by purification using all additives. The 
recombinant TMEGF 456 purified without any additives would serve as the control.  Successful 
completion of this experiment will tell us the approximate oxidation that occurs during the 
processing of urine sample. It should be pointed out that the minimization of oxidation during the 
processing would be advantageous for this research; however, it is not critical for its success. 
Since all the urine samples are subjected to the same purification method, the oxidation that 
could be occurring during processing should be the similar for all of them. When the methionine 
oxidation levels in smokers and non smokers are calculated, the oxidation that occurred during 
their respective purification, assuming they are equal, cancels out each other.    
The thrombin affinity chromatography was the very first method used to isolate 
thrombomodulin and it has been used in some other studies [184-186]. Dr. Deepika Talla, a 
former graduate student in our lab, had examined a method based on thrombin affinity 
chromatography. However, this method failed to produce significant thrombomodulin from urine 
apparently due to the following reasons. First, papers using thrombin affinity used some other 
steps prior or after to finish cleaning up the thrombomodulin, so it was not as simple in practice 
as it appears in theory.  Second, depending upon the glycosylation state of thrombomodulin there 
is variance towards its affinity for thrombin column [187].  Third, and most importantly, 
Komives’ group confirmed that thrombomodulin oxidation reduces thrombin affinity by a factor 
of 10. [94]  In our preliminary work, thrombin affinity columns, even used in fairly large excess, 
“leaked” some thrombomodulin and this thrombomodulin was presumably more oxidized.  This 
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method was therefore abandoned.  However, might some other form of affinity purification 
work? 
Antibodies might work, and should be explored in the future.  Aptamers are in vitro 
selected oligonucleotides that have high affinity and specificity towards their target [188, 189]. 
They are selected in a process called systematic evolution of ligands by exponential enrichment 
(SELEX), selection process involves screening for single stranded oligonucleotides sequences 
based on its binding affinity towards the target of interest [189-193]. DNA aptamers that bind to 
thrombin have been developed to capture thrombin using affinity phase stationary phase 
chromatography [193]. Thrombin was captured on stationary phase that had thrombin aptamer 
covalently attached to it. Proteins were loaded into the column, the non specific proteins were 
washed and bound thrombin was eluted using 20 mM Tris buffer containing 8 M urea, pH 7.3, at 
50 °C.  Our current protocol requires 2-3 samples of urine to be collected from each donor to 
isolate sufficient thrombomodulin to detect the peptide of interest in MALDI-TOF. 
Thrombomodulin binding aptamers could be developed and covalently bound to the stationary 
phase to conduct affinity based chromatography.   However, the greatest promise of aptamers is 
to skip the purification of the protein entirely.   
It is possible that aptamer that are specific to each of the oxidized and the reduced forms 
of thrombomodulin could be developed.  Previously, our group attempted to raise antibodies 
specific for the reduced and oxidized forms of thrombomodulin.  This was unsuccessful, possibly 
because of the high homology in this region of thrombomodulin between different mammalian 
species. If successful in developing aptamers for the oxidized and reduced form of 
thrombomodulin, one can imagine using them in an ELISA-like test of the amounts of each form 
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in urine or blood.  Such a test would be a great timesaving device, minimize the chances of 
oxidation, and would require much less sample. 
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CHAPTER 3: IS METHIONINE 388 OF THROMBOMODULIN MORE OXIDIZED IN 
CIGARETTE SMOKERS? 
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Introduction 
The blood of a smoker is more prone to clot than a non smoker; they are in 
hypercoagulable state. The narrowing of the arteries resulting from atherosclerosis increases the 
possibility of cardiovascular diseases [111], equally important is the hypercoagulable state seen 
in smokers. Cardiovascular diseases are the most common cause of death in smokers. The most 
common cardiovascular diseases seen in smokers are myocardial infarction and stroke. The fact 
that smokers have a hypercoagulable state has been established [194-197]; however, despite 
intensive research the molecular origin of such a state has not been shown. Free radical mediated 
oxidative damage to the endothelium is suggested to be an important factor for the development 
of cardiovascular diseases in smokers [112]. We hypothesized that oxidation of methionine 388 
of thrombomodulin results from smoking. We further hypothesize that oxidation of methionine 
388 in thrombomodulin is an important molecular factor leading to cardiovascular diseases in 
smokers.        
To understand why we feel thrombomodulin oxidation is important, one must first 
understand the role of this regulatory protein.  Thrombin when bound to thrombomodulin 
activates protein C. Activated protein C proteolytically destroys coagulation factors Va and 
VIIIa, thus suppressing further thrombin formation. The thrombin- thrombomodulin complex 
also activates the carboxypeptidase thrombin-activatable fibrinolysis inhibitor (TAFI) [198]. The 
activation of protein C and TAFI inhibits coagulation and fibrinolysis, making thrombomodulin 
a key protein for the regulation of coagulation and fibrinolysis.  
Thrombomodulin is found on endothelial cell surfaces [55, 56]. It was discovered by 
Esmon and Owen in the 1960’s. In rats, it is found predominantly in the lungs when compared 
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with other vascular organs like kidney and liver [57].  Thrombomodulin, purified from human 
lung endothelial membrane preparations, had an apparent MW of 78,000 Da [55]. Encoded by an 
intronless gene, the mature single-chain glycoprotein in the human is 557 amino acids long. 
Structurally it has 5 distinct domains. It has a short cytoplasmic tail at the C-terminus, which 
anchors thrombomodulin [58]. The deletion of this tail in mice does not have any effect in 
development, survival, coagulation and inflammation [58]. There is a well conserved membrane-
spanning domain, followed by a serine/threonine-rich domain with four potential sites for O-
linked glycosylation. The serine/threonine region supports the attachment of chondroitin sulfate, 
which is has 20 repeating disaccharide units and a terminal trisaccharide unit [59]. Adjacent to 
the serine/threonine-rich region is a domain that has 6 epidermal growth factors (EGF)-like 
repeats, this domain is the best characterized. This region shows disulfide bonding pattern that is 
seen in a typical protein-protein interactions. The first two EGF- like repeats, which are furthest 
from the serine/threonine rich region, remain unknown as to their function. EGF-like repeats 3, 
4, 5, and 6 [62-64] have been studied in detail by several groups and are essential for activation 
of Protein C by the thrombin-thrombomodulin complex. The cofactor function for 
thrombomodulin requires the last three of six tandemly repeated EGF-like domains (EGF 4, 5, 
and 6), as well as a Ser/Thr-rich domain between EGF-like domain 6 and the transmembrane 
domain. The residues 1 through 222 comprises N-terminal region of thrombomodulin, which 
constitutes almost half of the extracellular portion of the protein. The residues 155 through 222 
of thrombomodulin might be associated with plasma membrane and this region is hydrophobic 
[66].   
Thrombin binds to thrombomodulin to activate Protein C, which stops clotting by 
inactivation of clotting factors V and VIII [68]. The thrombin-thrombomodulin complex 
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activates protein C 1,000-fold more when compared to activation of protein C by thrombin alone.  
Deficiency in protein C or activated protein C is well established as increasing the risk of 
thrombosis [69]. Low levels of thrombomodulin are a well established risk factor for heart 
disease. Without a doubt, thrombomodulin plays a key role in slowing or stopping clotting.  
It has also been shown that thrombomodulin in complex with thrombin activates 
thrombin activatable fibrinolysis inhibitor (TAFI) by 1250 fold [72].  Activated TAFI is  a 
plasma procarboxypeptidase B that stabilizes clot by down regulating fibrinolysis [76]. Activated 
TAFI catalyzes the removal of lysine residues from the C-terminal of fibrin, resulting in 
elimination of plasminogen binding site of fibrin, subsequently plasminogen is unable to activate 
and prevention of fibrinolysis [79, 80]. This function of thrombomodulin might seem 
contradictory to its pro-fibrinolytic function previously discussed, but this highlights that 
thrombomodulin is a key regulator in coagulation, since it controls both the formation and 
breakdown of clots.  
Thrombomodulin is anchored on the luminal surface of the endothelium and as 
previously indicated, thrombomodulin lacking the cytoplasmic domain appeared normal. 
Thrombomodulin undergoes endocytosis and degradation, but a significant amount of it is 
cleaved off and it is found in blood. Thrombomodulin found in blood is heterogeneous in size, 
due to differences in glycosylation [81, 82] and proteolysis. Four different fragments have been 
isolated from blood and seven fragments ranging in size from 12 to 100kDa after reduction of 
disulfides [83] . The concentration of thrombomodulin in serum and plasma are reported to be 
between 3 to 300ng/mL [84]. In diseases like diabetes and lupus high levels of thrombomodulin 
in plasma have been reported, this is believed to be a good marker for endothelial damage [198].  
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Studies have correlated high plasma thrombomodulin levels to be associated with a low risk of 
developing coronary heart disease [198]. 
The fourth and the fifth EGF like domains of thrombomodulin consists of 81 amino acids 
in together, and the fifth domain contains most of the residues that bind to thrombin [87]. The 
EGF like domain 4 and 5 (TMEGF45) bind to thrombin more tightly than EGF 5 alone. 
TMEGF45 is the smallest fragment of thrombomodulin that when bound to thrombin can 
activate protein C. Addition of fourth and the fifth EGF-like domains separately, do not activate 
protein C, suggesting they work together in activation of protein C [88].  The kcat values for 
protein C activation by the thrombin-TMEGF45 complex, calculated by binding kinetic studies 
and cofactor activity assays, shows TMEGF45 has full cofactor activity. The EGF like domain 
six increases the Km value of thrombomodulin for thrombin by factor of ten, despite not altering 
the Kcat value of  thrombin-thrombomodulin complex for protein C [89].    
 The EGF 4 and 5 of thrombomodulin is linked together by three residues, and one of 
them is methionine, which is the 388
th
 residue in thrombomodulin (Met388). Met388 in 
thrombomodulin is conserved in bovine, mouse and human. The mutation of Met388 to any 
other residues, except leucine, decreases the anticoagulant cofactor activity of thrombomodulin 
[91].  More importantly, there is 76-90% loss of activity when Met388 is oxidized using H2O2 
[92].  There are four other methionine residues found in thrombomodulin, but their oxidation 
does not disrupt the ability to activate Protein C [92]. The Kd of thrombomodulin thrombin 
interaction increases to 10.9 from 4.4nM, when a full length thrombomodulin had oxidized 
Met388 [93]. TMEGF45 with oxidized Met388 has 3.5 fold lower Kcat, and 3.3 fold higher Km 
values when compared to wild type TMEGF45 based on protein C activation assays [94]. It must 
also be mentioned that clot stabilizing activation of TAFI by thrombin-thrombomodulin complex 
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is unaffected by the oxidation of Met388 [95]. Since the activation of clot stabilizing activated 
TAFI, a procoagulant pathway, is unaffected by Met388 oxidation, while activation of protein C, 
an anticoagulant pathway, is suppressed by oxidation of Met388, there is no question that 
methionine oxidation favors coagulation. Although the effects of oxidation of Met388 on 
activation of protein C and TAFI were demonstrated in vitro, it seems likely that oxidation of 
Met388 in vivo would lead hemostasis towards coagulation.  
 Our hypotheses state that the oxidation of methionine 388 in thrombomodulin is higher in 
smokers when compared to non smoker. It is our belief that this oxidation is a key molecular 
cause of the prethrombotic state in smokers and thus a critical factor in the development of 
thrombosis and premature death in smokers. The case for relationship between smoking and 
oxidation of thrombomodulin as an important player in cardiovascular diseases has also been 
published by the Fernández group [117]. The circulating levels of protein C was compared in 
smokers and non smokers, activated protein C was 23% lower in smokers than nonsmokers. One 
of the possible causes of low levels of protein C could be due to the reduced thrombomodulin 
activity in smokers, probably due to methionine 388 oxidation.   We have successfully purified 
significant quantities of thrombomodulin from urine from multiple donors, both smokers and non 
smokers, and quantified the relative oxidation levels in them.    
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Materials and Methods 
The University of Arkansas Institutional Review Board approved all experimental 
protocols using human subjects.  Samples of the first morning urinate were collected by 
volunteers in 400 mL centrifuge bottles. Thiodiglycol (5 mL) and 0.5 M EDTA (1 mL, pH 8.0) 
were added to containers before sample collection. The collected samples were transported using 
an insulated bag containing an ice pack. The samples were generally transported to the 
laboratory within two hours of collection and stored at 4°C for no longer than 2 hours before 
further processing to minimize the opportunity for oxidation. Typical volumes of the sample 
from a donor ranged from 200-550 mL. Prior to processing, 1 mL of sample was removed and 
stored in -80°C for determination of the initial thrombomodulin concentration in the sample. The 
samples were centrifuged in a Sorvall GS-3 rotor at 4,000 rpm for 30 min at 4°C. The samples 
were then filtered using a bottle-top 0.22 µm polyethersulfone (PES) membrane filter to remove 
remaining particulates and cellular debris. Sufficient 0.25 M imidazole acetate buffer, pH 6.0 
was added to the urine filtrate to bring to a final concentration of 25 mM imidazole acetate. Next, 
the pH of the sample was adjusted to 6.0 by addition of 2 M acetic acid or 6 M NaOH depending 
on the urine sample. Typically after the addition of 0.25 M imidazole acetate buffer, the pH of 
the samples ranged from pH 5.5-6.4.The pH of the sample was measured using a pH electrode. A 
slurry of Q Sepharose FF (GE Healthcare) was poured into a 50 mL Bio-Rad Econo column in a 
sufficient amount to pack a 20 mL bed volume.  A Fluid Metering, Inc (FMI) pump was 
connected to the Bio-Rad column to pump buffer and urine sample through the Q Sepharose FF 
column at a constant speed of 5 mL/min. The column was first equilibrated with 60 mL of 25 
mM imidazole acetate buffer, pH 6.0. Next, the urine sample was passed through the column. 
The column was washed with 50 mL of 25 mM imidazole acetate buffer, pH 6.0 and then by 
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addition of 20 mL of 25 mM imidazole acetate buffer, pH 6.0, 50 mM NaCl. Fractions 
containing thrombomodulin were eluted by addition of 50 ml of 25 mM imidazole acetate buffer, 
pH 6.0, 0.5 M NaCl. The 0.5M NaCl fractions were collected in 15 mL conical tubes, 5 mL in 
each tube. The eluent after addition of 25 mL of 25mM imidazole acetate buffer, pH 6.0, 0.5 M 
NaCl, tested positive for thrombomodulin. A solution of 0.2 M L-methionine (Sigma-Aldrich) 
was added to thrombomodulin containing fractions to a final concentration of 2 mM methionine. 
The fractions were transferred to 1.5 mL microcentrifuge tubes, typically 14 tubes, and flash 
frozen in liquid nitrogen. The frozen eluent in 1.5 mL microcentrifuge tubes was dried under 
vacuum in a SpeedVac concentrator system using medium heat.   
Reverse phase HPLC purification 
The dried samples from ion exchange were pooled and dissolved in minimum volume, 
generally 5 mL of total volume, of 18.2 megaohm deionized water. The dissolved sample was 
passed through a 25 mm syringe filter with 0.2 µM PES membrane (VWR).  The redissolved 
sample was injected into a reverse phase Waters HPLC system. An Atlantis dC18, 5 μm particle, 
4.6x250 mm column held at 58°C and a 2996 photodiode array detector monitoring 214 nm and 
254nm was used. The maximum volume that could be injected into Atlantis dC18, 5 μm particle, 
4.6x250 mm column per run is 1.4 mL. The total volume of the sample to be injected into the 
HPLC was 5 mL, 4 different HPLC runs had to be performed to purify entire sample. Upon 
injection, a gradient was run at 1 mL/min from 10 to 29% acetonitrile, 0.1% trifluroacetic acid 
over 12 minutes, and then from 29% to 40% acetonitrile over the next 11 minutes, and then from 
40% to 90% acetonitrile over the next 25 minutes. Eluent was collected in 1 mL fractions in 1.5 
mL microcentrifuge tubes, to which were previously added 100 uL of 200 mM Tris buffer, pH 
8.0. The thrombomodulin containing fragments, identified by ELISA, typically eluted at 30 
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minute. Thrombomodulin containing 1.5 mL microfuge tubes were flash frozen in liquid 
nitrogen, dried under vacuum in a SpeedVac concentrator system using medium heat.  The HPLC 
Atlantis column was cleaned using 1.0 mL/min of 90% MeCN/0.1% TFA for 10 minutes, 
followed by equilibration for 15 minutes to the starting conditions of 1.0 mL/min of 10% 
MeCN/0.1% TFA in preparation for the next injection. 
Digestion of thrombomodulin 
The dried thrombomodulin containing fractions from the reverse phase chromatography 
were pooled and dissolved in approximately 100 uL of 1X phosphate buffered saline (PBS; 1.46 
mM KH2PO4, 9.9 mM Na2HPO4, 2.68 mM KCl, 137 mM NaCl, pH 7.4). Based on the previous 
attempts with chymotrypsin digestion of thrombomodulin after HPLC purification, we observed 
the samples that were cloudy did not undergo digestion with the protease. The samples that were 
cloudy prior to digestion were spun in a microcentrifuge (Galaxy 14D VWR) at 13K RPM for a 
minute. The supernatant was removed. The precipitate was dissolved in 75 µL of 1X phosphate 
buffered saline, and was used for digestion. Freshly prepared tris-carboxyethylphosphine (TCEP) 
was added to make the final concentration of 50 mM TCEP. 10 µL of 0.5 M sodium phosphate 
buffer pH 7.5 added to the sample, prior to addition of 500 units of PNGase F (New England 
Biolabs). The samples were incubated at 37°C for 4 hours to deglycosylate the sample. The 
protein was then digested at 30°C for 8 hours after adding 4.1 μg of sequencing grade 
chymotrypsin (Princeton Separations) dissolved in 50 mM Tris-HCl, 1 mM CaCl2, pH 8.0. The 
chymotrypsin was inactivated by placing the samples in a 100°C dry bath for 30 seconds. The 
samples were immediately flash frozen, and stored in -20°C until further processing.   
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Mass spectrometry analysis of methionine 388 oxidation 
The semi quantification of oxidized and reduced forms of peptide in the chymotrypsin 
digested thrombomodulin was conducted by matrix-assisted laser desorption/ionization 
(MALDI) mass spectrometry. The MALDI analysis was performed by the Statewide Mass 
Spectrometry Facility located at the University of Arkansas. The pure samples were mixed with 
the MALDI matrixes. The two types of matrixes used were alpha-cyano-4-hydroxycinnamic acid 
(CHCA) and 2,5-dihydroxybenzoic acid (DHB) (Sigma Aldrich).  MALDI-TOF mass spectra 
were obtained on a Bruker Ultraflex II (Bruker Daltonic GMBH, Bremen, Germany) time-of-
flight mass spectrometer operated in the positive-ion reflectron mode.  The accelerating voltage, 
delayed extraction time, and laser power were adjusted to optimize sensitivity and resolution for 
ions between m/z 500 – 4000. 
UPLC injections of synthetic peptide 
The stock solution of the synthetic peptide was diluted using 18.2 megohm water to make 
following concentrations: 100, 10, 1, and 0.1 mM. Injections of 25 uL of each of these solutions 
were performed on the Waters ACQUITY UPLC system, detector monitoring 214nm. A BEH 
130 C18 1.7 µm 2.1x150 mm, reverse phase column heated to 45°C, 0.2 mL/min flow rate was 
used to separate the peptide mixture.  The eluent was started at 10% MeCN/0.1% TFA and 
transitioned to 20% MeCN/0.1% TFA in a linear gradient over two minutes.  Over the next 25 
minutes, a linear gradient from 20% MeCN/0.1% TFA to 90% MeCN/0.1% TFA was run. 
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Results and Discussion 
This study was undertaken to quantify the relative oxidation of methionine 388 of 
thrombomodulin from smokers and non smokers. Cigarette smoke is a complex mixture of 
chemical compounds, including high concentrations of reactive oxygen species and reactive 
nitrogen species [12]. Also important is the secondary oxidative stress triggered by ROS and 
RNS from cigarette smoke. The lungs of cigarette smoker are exposed to primary and secondary 
oxidation from cigarette smoke. Since thrombomodulin is predominantly found in the lungs, we 
hypothesize that in smokers it is subjected to significant levels of oxidation from cigarette 
smoke.     
There are several challenges associated with quantifying the oxidation of 
thrombomodulin purified from urine. The thrombomodulin is cleaved into fragments prior to its 
circulation in the urine and combined with the heavy mass of the fragments make direct 
quantification impossible. Also, the thrombomodulin is heterogeneous in size due to differences 
in glycosylation [81, 82]. Peptide mass fingerprinting provides a significantly easier alternative 
compared with working with bigger protein fragments. In this technique the protein of interest is 
cleaved, and the mass of the resulting fragments is measured using mass spectrometer.  
Chymotrypsin digestion of thrombomodulin results in the fragmentation of the protein 
into several peptides. Among the peptides of digest, the peptide APIPHEPHRCQMF is the prime 
interest for the purposes of this study. This peptide is composed of residues 377-389 of 
thrombomodulin. The second to the last methionine residue corresponds to the 388
th
 residue. In 
the naturally occurring thrombomodulin this peptide can exist in two different forms; 
APIPHEPHRCQMF and APIPHEPHRCQMoxF. The former is a relatively non polar peptide and 
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its isotopically averaged mass is 1562.73 Da. The latter is more polar than its counterpart, and its 
mass is 1578.74 Da.  
Depending on the state of methionine 388 of thrombomodulin, the chymotrypsin 
digestion should result in differences in the resulting peptides. If the methionine 388 is 
exclusively present in the reduced state, the digestion will only produce APIPHEPHRCQMF. In 
the case of methionine completely oxidized to methionine sulfoxide, the digestion results in 
exclusive presence of APIPHEPHRCQMoxF. If the methionine 388 is partially oxidized the 
resulting digest will have presence of both oxidized and the reduced forms of the peptide. The 
presence of either forms of the peptide can be confirmed by MALDI-TOF. The MALDI-TOF 
measurement also provides the relative signal intensity of the peptides in the sample. The 
intensity of the signal from each peptide is proportional to its concentration in the sample.  
Comparing the intensity of different peptides can be problematic though, because each peptide 
has a different tendency to ionize and thus be detected.  Nevertheless, the intensity of reduced 
and oxidized peptide in MALDI-TOF measurement can be used to calculate the approximate 
ratio of oxidized and reduced forms of APIPHEPHRCQMF in thrombomodulin. Figure 3.1 is 
MALDI-TOF spectra of digested thrombomodulin purified from urine. This urine sample was 
collected from a 28 year old male smoker.  The intensity of the signal from the reduced peptide 
is approximately three fold higher than that of the oxidized form in this particular sample.  
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Figure 3.1: MALDI-TOF mass spectra of chymotrypsin digested thrombomodulin purified from 
urine. Urine sample was collected from a 28 year old male smoker. 
UPLC injections of synthetic peptide 
Acquity UPLC offers increased resolution, sensitivity and speed when compared to 
HPLC. It uses small particle columns (1.7 µm – 1.8 µm), which improves system efficiency by 
producing better resolution, and also lowering the analysis time. This system is designed to 
minimize band spreading resulting from the column and also from the instrument. The stock 
solution of the synthetic peptide APIPHEPHRCQMF (Sigma) was diluted with 18.2 megohm 
water to make 100, 10, 1, and 0.1 mM solutions. The commercial peptide is mixture of both 
oxidized and reduced peptides, APIPHEPHRCQMoxF and APIPHEPHRCQMF. 25 uL of each of 
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the diluted solutions were injected into the Waters ACQUITY UPLC System. This system is 
much more suitable for quantitative analysis than MALDI. The accurate ratio of reduced and 
oxidized peptide in each of the solution can be obtained by using the UPLC. The relative area 
occupied by the reduced and the oxidized peptide in the UPLC chromatogram can be used to 
calculate the ratio of the peptides in each solution. Figure 3.2 is the Acquity UPLC 
chromatogram of 25 µL injection of 1 mM synthetic peptide. The ratio of reduced and oxidized 
peptide in 0.01 M synthetic peptide solution is 3.26.  
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Figure 3.2: Acquity UPLC chromatogram of 25 µL injection of 1 mM synthetic peptide. The 
oxidized and reduced peptide elute at 11.2 and 18.7 min respectively. The area occupied by the 
oxidized and the reduced peptide is 23.47% and 76.53%. The synthetic peptide purity was >85%, 
hence the presence of other peaks in this chromatogram.  
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Peptide 
concentration(mM) 
Area of reduced 
peak (%) 
Area of oxidized 
peak (%) 
Ratio of 
peptides 
100 76.49 23.51 3.25 
10 76.46 23.54 3.25 
1 76.53 23.47 3.26 
0.1 76.58 23.42 3.27 
 
Table 3.1: Ratio of the reduced and oxidized peptides in different concentrations of synthetic 
peptide, acquired using a Waters Acquity UPLC.  
    
Table 3.1 shows the ratio of the reduced and oxidized peptide in 100, 10, 1, and 0.1 mM 
solutions of the synthetic peptide. The ratio of reduced and oxidized peptide in each solution was 
calculated using the relative area occupied by each peptide in the UPLC chromatogram at 214 
nm absorbance. Since sulfoxide does not absorb significantly at this wavelength, the amount of 
material present in each peak should be directly proportional to the peak areas.  In the UPLC 
chromatogram of 100 mM synthetic peptide, the reduced and oxidized peptide occupied 76.49% 
and 23.51% area respectively. Based on that information, the ratio of reduced and oxidized peak 
in the 100 mM solution was calculated to be 3.25. The mean ratio for the four different solutions 
was 3.25 with a standard deviation of 0.01.    
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We attempted to use Acquity UPLC to directly quantify the oxidation of methionine 388 
of thrombomodulin purified from urine. The synthetic peptide mixture was injected into the 
UPLC to map the peptide. Under these conditions, the oxidized and reduced peptide elute at 12 
and 21 min respectively (Figure 3.3).  
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Figure 3.3: Acquity UPLC chromatogram of the commercial peptide mixture. 
APIPHEPHRCQM(ox)F elutes at 12 min and APIPHEPHRCQMF elutes at 21 min. 
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The chymotrypsin digested urinary thrombomodulin was injected into the UPLC system. 
Unfortunately, there were several contaminating peptides that eluted very near or even co-eluted 
with the peptide of interest. Despite trying numerous elution profiles, the resolution necessary to 
calculate the relative area occupied by the oxidized and the reduced peptide often could not be 
achieved using the UPLC.  The digested samples had slightly different elution times from the 
synthetic peptides and co-injected samples had slightly different elution times still.  These 
problems were exacerbated when of the two peaks was only minimally present.  It was, in those 
cases, difficult to be sure which peak was the one of interest. It is possible that a good UPLC-MS 
system could overcome these difficulties, but attempts to interface our UPLC directly with a 
mass spectrometer failed because none of the mass spectrometers available to us had high 
enough scan rates.  Peaks were often not detected by MS.  The use of UPLC to calculate the 
methionine oxidation was therefore discarded.    
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Figure 3.4: UPLC chromatogram of chymotrypsin digested urinary thrombomodulin of a 26 year 
old Caucasian male non smoker. The two forms of peptide elute at 12 and 21 min respectively, 
notice the contaminating peaks at those times.   
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Figure 3.5: Overlay of UPLC chromatograms. Top chromatogram is of chymotrypsin digested 
urinary thrombomodulin of a 26 year old Caucasian male non smoker, and the bottom 
chromatogram is of synthetic peptide mixture. 
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Accuracy of quantification by MALDI 
Matrix-assisted laser desorption ionization (MALDI) is a powerful technique for mass 
spectrometry of peptides and proteins [178]. This technique provides fast and accurate 
acquisition of molecular mass and purity. Some of the advantages offered by this instrument are 
follows: It is very easy to operate and it is tolerant towards the presence of buffers, salts and 
other additives. It can be used for analysis of compounds with a MW over 300 KDa [199]. It 
ionizes the analytes very softly; usually only M+H
+
 and a small amount of M+2H
+
 ions are 
generated making analysis of mixtures feasible. Briefly, solution of analyte is mixed with the 
matrix (2,5-dihydroxybenzoic acid) directly on a target, and evaporation produces crystals which 
are a mixture of the analyte and matrix. The laser UV pulse is directed on the matrix/analyte 
crystals, matrix ionizes and transfers charge to the analyte, and the ionized matrix and analyte 
vaporize and expands into gas phase. Despite its popularity with analysis of proteins and 
peptides, this technique is considered impractical for the analysis of analytes that have low mass 
and for quantitative analysis [200]. The presence of excess matrix can blanket the low m/z signal 
in the spectrum that corresponds to the analyte with low mass.  
Quantitative analyses are not generally attempted in MALDI because there is not a 
uniform distribution of the sample and the matrix on the surface of the target. This creates a 
variability of the analyte within the matrix, and as a result there is significant variability in the 
peak intensities, baseline, and noise level seen in MALDI spectra from the same sample [200]. 
Another challenge in conducting quantitative studies of complex sample using MALDI is the 
competitive ionization and ion suppression. Some analytes have greater affinity for charge than 
others and they are more competitive in obtaining available proton. For example, peptides that 
terminate in arginine have higher affinity in charge when compared to peptide that ends with 
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lysine [201]. However, for our purposes the difference in ionization efficiency of different 
components in the sample is less important, since we are only interested in two versions of a 
single peptide. Also, to enhance the quantitative ability of MALDI, alpha-cyano-4-
hydroxycinnamic acid (CHCA) was used as a matrix to produce an ultrafine homogenous 
sample-matrix composition.  It showed better sensitivity and reproducibility compared to 
traditional dried droplet preparations using 2,5-dihydroxybenzoic acid (DHB) [202, 203].     
The accuracy and the precision of MALDI-TOF can be directly tested using synthetic 
peptide APIPHEPHRCQMF. The commercial peptide is mixture of both oxidized and reduced 
peptides, APIPHEPHRCQMoxF and APIPHEPHRCQMF. The stock peptide was diluted using 
18.2 megohm water to prepare 100, 10, 1, and 0.1 mM solution of the synthetic peptide. These 
solutions were sent for MALDI analysis. For each sample, three different sample-matrixes were 
prepared, and each of the sample/matrix was subjected to approximately 5000 shots. Table 3.2 
shows averaged intensity values from these 5000 shots for reduced and oxidized peptide in 100, 
10, 1, and 0.1 mM solutions of the synthetic peptide. MALDI of 1 µL (5 pmol) of 0.01 mM 
synthetic peptide did not produce a detectable signal for oxidized peptide. 
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Peptide 
concentration 
(mM) 
Intensity of Reduced 
Peptide (A.U) 
Intensity of Oxidized 
Peptide (A.U) 
Ratio of 
Intensities 
(red/ox) 
100 14000 1000 14 
10 12500 1500 8.3 
1 5400 1000 5.4 
0.1 2300 250 9.2 
 
Table 3.2: The average MALDI spectra intensities of reduced and oxidized synthetic peptide in 
four different solutions. Three sample-matrixes were mixed for each solution, and each sample-
matrix was subjected to approximately 5000 shots. The table provides average values from these 
shots (A.U = arbitrary units).  The fourth column is the ratio of the second and the third column. 
MALDI of 1 µL of 0.01 mM solution of peptide did not produce a signal for oxidized peptide. 
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The 100, 10, 1, and 0.1 mM solutions of the synthetic peptide were prepared by serial 
dilution of the stock solution of the synthetic peptide. The ratio of reduced and oxidized peptides 
in each of the solutions should be same even after the dilutions. The fourth column on Table 3.2 
provides the ratio of the two forms of peptides in each of the solutions, the mean of the ratios is 
9.2, and standard deviation is ± 3.6. Clearly, the Acquity UPLC system is much more suitable for 
quantitative analysis compared to MALDI and, when it was used to measure the mean ratio of 
reduced and oxidized peptide in each solution (Table 3.1), the calculated mean was 3.25. With 
such low accuracy and precision, the use of MALDI for quantification of two forms of peptide in 
a sample is challenging. MALDI overestimates the amount of the reduced form and the 
measurement is much more variable.  However, if the differences in thrombomodulin methionine 
388 oxidation in cigarette smokers and non smokers are large enough, these weaknesses do not 
prevent detection of dissimilarities. 
Relative methionine oxidation in smokers and non smokers   
There are a few definitions we use to classify our donors. A cigarette smoker is someone 
who has been smoking for at least the past six months, smokes a minimum of 5 cigarettes per 
day, and does not smoke anything other than tobacco (e.g. marijuana).  A non-smoker is 
someone who has not smoked in over six months and does not use any other form of tobacco and 
is not heavily exposed to secondhand smoke. A never-smoker is a non-smoker that has never 
smoked. A secondhand smoker is an otherwise non-smoker who is heavily exposed.  A former 
smoker is someone who has not smoked for least six months. 
 We wanted to minimize the variables that are linked with oxidation in this research. For 
example, a donor who has diabetes would be under increased oxidative stress, and such condition 
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would increase the uncertainty of our results. The donors were carefully screened to eliminate 
the ones who could be under greater oxidative stress than normal. Potential donors with known 
history of cardiovascular diseases, diabetes, high blood pressure, hyperhomocysteinemia, severe 
arthritis, renal failure, current use of anti-coagulants, recent surgery, extreme use of over-the-
counter anti-oxidant vitamins, chronic allergies or infection, and pregnancy were excluded from 
this study.  
In this study a smoker donor was matched with non-smoker control, and the difference in 
methionine 388 oxidation between the two was measured. It was very important to minimize the 
variables that affect oxidation in the smoker and the control. In our study smokers were matched 
with controls based on age, gender, and race. We understand that the oxidation of 
thrombomodulin could be affected by multitude of factors such as diet, differences in expression 
of repair proteins, variability in expression of thrombomodulin, and many other possibilities, and 
it would be impossible to eliminate all variables between the smokers and the control.     
The oxidation of methionine 388 of thrombomodulin was studied in six non smokers (Table 3.3) 
and 13 smokers (Table 3.4). In the two out of six non smokers the MADLI spectra did not report 
the presence of oxidized peptide. The average ratio of reduced and oxidized peptides in four non 
smokers was 1.5. The concentration of reduced peptide was higher. Conversely, six of the 
thirteen smoker subjects did not have reduced peptide in the MALDI spectra (Table 3.4). The 
average ratio of reduced and oxidized peptide for the seven smokers was 0.58. The ratio of 
oxidized peptide was higher in cigarette smokers. The reduced/oxidized ratio and percent 
oxidation in Tables 3.3 and 3.4 must not be taken literally.  We know that MALDI tends to either 
overestimate the level of reduced peptide or underestimate the level of oxidized peptide or some 
combination of both.  In other words both non-smokers and smokers are likely to be actually 
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much more oxidized than the values in the two tables indicate.  However this systematic error is 
similar for both populations.  While we cannot say exactly how much the oxidation levels differ, 
we can examine whether the differences observed are statistically significant. 
The presence of completely reduced peptides in two non smokers, and presence of 
completely oxidized peptide in six smokers and the relative ratio of the two forms of peptides in 
smokers and non smokers clearly indicate that the methionine 388 of thrombomodulin in 
cigarette smoker is significantly oxidized in smokers. In order to perform the t-test, we revisited 
each of the MALDI spectra of digested thrombomodulin and recorded the noise level. The noise 
level was multiplied by the factor of 2.5. This value was assigned for the peptide which was not 
detected in the MALDI spectra.  This, of course, is a very conservative estimate for the amount 
of the peptide that was not detected and most of the actual values are likely much less than this.    
The ratio of the reduced to oxidized peptide MALDI data from smokers and non smokers passed 
the Shapiro-Wilk test for normality (P=0.068) and an equal variance test (P=0.111). Statistical 
comparisons were performed using Student's t-test (t= 3.72, P=0.001). Thus, there is a very 
statistically significant difference between thrombomodulin methionine 388 oxidation in 
smokers and non smokers, despite using very conservative estimates.  
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Figure 3.6: MALDI-TOF spectra of chymotrypsin digested urinary thrombomodulin of 25 year 
old caucasian male never smoker (Donor code: NS 36, Table 3.3). The spectrum shows presence 
of both reduced and oxidized peptides. The signal to noise ratio is greater than 10 for both forms 
of peptide.  
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Table 3.3 : MALDI spectra values of oxidized and reduced peptides in non smokers. NS = Non 
smoker, ND = Not Detected, Red = Reduced, Ox= oxidized, A.U. = arbitrary units, M = male, F 
= female, C = Caucasian 
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Table 3.4: MALDI spectra values of oxidized and reduced peptides in cigarette smokers. CS = 
cigarette smoker, ND = not detected, Red = reduced, Ox= oxidized, M = male, F = female, A.U 
= arbitrary units, C = Caucasian, SEA = South East Asian. Daily intake is the number of  
cigarettes smoked per day.  Noise is the background noise of the spectra. % oxidized is the 
percentage  of oxidized peptide. 
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 It is necessary to consider what the effects are of assuming that the amount of any peak 
that is not detected is equal to 2.5 times the noise level.  Again, this is a conservative assumption 
that has the effect of making the average non smoker seem more oxidized and the average 
smoker less oxidized.  This moves the two averages toward each other, but also tends to make 
them more normally distributed.  If we assume that the peak that is not detected is present in the 
same amount as the noise level (data not shown), the data are no longer normally distributed, 
failing the Shapiro-Wilk test.  However, using the non-parametric Mann-Whitney Rank Sum test 
we discover, unsurprisingly, that the difference in the median values of the two groups (Red/Ox 
median non smoker 2.043; smoker 0.308) is still greater than would be expected by chance 
(P=0.002).   
In a few cases a peak was detected which was greater than the noise level but not 2.5 
times larger.  We examined the effect of excluding these individuals entirely if both peaks were 
below this cut-off while if just one of the two peaks was detected, but below 2.5, increasing it to 
2.5 the noise level.  The data passed the Shapiro-Wilk test (P=0.516) but failed the equal 
variance test, presumably because only three values were left for the non smokers.  However, the 
Mann-Whitney test still showed that the difference (Red/Ox median non smoker 2.498; smoker 
0.310) between the two groups was quite significant (P=0.015). Clearly, there is a stastically 
significant difference between the two populations. 
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Possible Future Work  
In the future we would like to expand this study to greater numbers of participants to 
determine how oxidation varies for the many permutations of smoking behavior.   We plan to 
recruit smokers with a wide range of cigarette consumption habits.  We expect a relationship 
between higher levels of smoking and higher oxidation, and our hypothesis would be further 
supported if we can establish there is a dose dependent curve. While conducting this study, we 
expect some donors to display variably that would not be consistent with dose dependent curve.  
Determining the degree to which there is variability which is not explained by the amount of 
smoking is very important. It is possible that some individuals resist the oxidation of 
thrombomodulin better than others.  This could be due to multitude of factors some of which 
could be diet, environment, differential expression of repair proteins, and differential expression 
of thrombomodulin. Identification of such individuals offers extension of this research project. 
Firstly, we would identify the factors that make them vary from normal smoking behavior. Next 
steps would be identifying how influential individual factors are by themselves, and eventually 
their effects in myriad permutations and combinations.    
Pipe and cigar smokers typically do not inhale the smoke, and that differentiates them 
from cigarette smokers. We are interested to see how pipe and cigar smoke affects 
thrombomodulin. Since these smokers typically do not inhale the smoke this offers a very useful 
avenue for testing the hypothesis that the bulk of thrombomodulin oxidation in cigarette smokers 
is localized to the lungs.  It would be informative to recruit smokeless tobacco users, and 
compare the thrombomodulin oxidation levels. 
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The American Heart Association has concluded that passive smoking is an important risk 
factor for heart disease in both adults and children [204]. AHA estimates 22,700 to 
69,600 annual premature deaths from heart and blood vessel disease are caused by passive 
smoking [205]. We would like to examine the effects of secondhand smoke on non-smokers, by 
recruiting donors who live with smokers or donors working in a bar.  It is difficult predict 
whether we will be able to detect a measurable, and statistically significant oxidation in 
secondhand smokers, but in light of our research findings, we believe it will be worthwhile to 
quantitate thrombomodulin methionine oxidation in second hand smokers. The degree of 
cigarette smoke is measured by counting the number of cigarettes smoked in a day, however for 
the second hand smoke study we need a quantitative test to record cigarette smoke inhaled by the 
donor. The self reported method by the non smokers are going to be inaccurate due to multiple 
factors some of which are proximity of nonsmokers to smokers, ventilation of the room, and 
individual differences in exposure sensitivity. Nicotine  would be an ideal biomarker for this 
study, however it has a half life of 2 hours making it unsuitable [206]. Nicotine from tobacco 
smoke when taken into the lungs enters into the bloodstream. When nicotine in the blood stream 
reaches liver it is processed into cotinine, which is the principle metabolite of nicotine from 
tobacco smoke.  Cotinine and has been documented to be a sensitive and specific marker for 
tobacco exposure [207]. It is found in saliva, plasma and urine [208].  Urinary cotinine 
concentration has been shown to be accurate biomarker for tobacco exposure [208-210]. The 
degree of cigarette smoke exposure of the passive smoker can be measured using cotinine 
ELISA. The thrombomodulin methionine 388 oxidation is passive smokers can be studied using 
our current protocol combined with cotinine as a biomarker.    
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The MALDI spectra of chymotrypsin digested thrombomodulin from non smokers and 
smokers gave us insight into methionine 388 oxidation. We have established that methionine 388 
of thrombomodulin in smokers is more oxidized, and we propose that the oxidation of 
methionine 388 in thrombomodulin could be one of the key molecular causes for cardiovascular 
diseases in cigarette smokers. The immediate extension of this research would be to find 
treatment that would reduce the oxidized methionine 388 of thrombomodulin. Since cigarettes 
are the ones imposing oxidative stress the first step towards treatment would be for a smoker to 
quit smoking cigarettes. We could set up an experiment where a smoker is willing to quit 
smoking. The urine samples will be collected at frequent intervals before and after the donor 
quits. The samples would be collected for six months from the date the smoker quits smoking, 
with cotinine tests to verify abstinence. The MALDI data collected over that span will be 
analyzed to see if there are any changes to the oxidation levels of methionine. We speculate that 
the oxidation levels to decrease. Six months ago we found a donor who volunteered to quit 
smoking cigarettes for this study. Urine samples were collected for a span of 1 month before the 
donor quit smoking, and samples have been collected at a frequency of 3 weeks interval. The 
urine samples have undergone reverse phase HPLC step of purification, and are currently stored 
in -20˚C. When the donor completes 6 six months without smoking, the stored samples will be 
subjected to chymotrypsin digestion and will be sent for MALDI analysis. We are actively 
looking for donors who plan on quitting smoking. In the past few months we have found three 
donors who planned on quitting, and two of them did quit, but only for the span of 1-2 weeks. 
We could approach smoking cessation clinics to recruit smokers trying to quit.  The state of 
Arkansas has chosen to use some of its tobacco settlement money to subsidize the cost of 
clinically proven programs, which means that there are a number of fairly popular and successful 
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programs working in the area. Experiments where many permutations of donors who quit 
smoking could be designed based on age, sex, race and degree of smoking, and compare each 
factor towards recovery. For comparison, if we could find a donor who intends to pick up 
smoking would provide us insight on rate at which cigarette smoke oxidizes methionine 388 of 
thrombomodulin.  
Annually 437,900 people are killed by diseases caused by smoking, and 35% of those 
deaths are cardiovascular related [20]. Cigarette smoke is the major cause of pulmonary 
emphysema [21], bronchitis, myocardial infarction, and stroke as well as lung cancer. Four 
million people die every year from tobacco smoking related diseases worldwide. It has been 
estimated that 2 billion people use tobacco products [22].  Approximately 64.5 million people in 
the USA are active smokers, between 1995-1999 the estimate of deaths that resulted from 
smoking and exposure to secondhand smoke was approximately 440,000 annually [23]. Cigarette 
smoking ranks number one in the list of preventable disease and death worldwide. In 2004, 
cigarette smoking cost the United States over $193 billion, this number includes $97 and $96 
billion from loss in productivity and in direct health care expenditures respectively [211]. The 
average cost to the government was $4,260 per adult smoker [211]. As we have mentioned 
previously, we propose methionine 388 oxidation is one of the key molecular mechanism for 
development of cardiovascular diseases in smokers. Treatment to mitigate or regress methionine 
388 oxidation in smokers has potential to minimize or prevent morbidity and fatality in cigarette 
smokers. We could design experiments where mice are subjected to cigarette smoke for a period 
that would induce cardiovascular like symptoms. Following the development of disease, they are 
treated with antioxidants like apocynin or Tempol [212-214], and the effectiveness of the 
antioxidants is monitored.  
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Prolylcarboxypeptidase (PRCP) is an endothelial membrane-bound serine 
carboxypeptidase responsible for activation of bradykinin and angiotensin [103-105]. Both 
proteins regulate the vascular NO to provide protection from thrombosis. PRCP is indirectly 
involved in maintenance of normal blood pressure and reduction of thrombosis risk. PRCP 
polymorphism has been associated with hypertension and inflammation [106]. PRCP gene-
trapped mice are hypertensive and are prone to faster thrombosis [107]. These mice have 
increased in vivo vascular ROS and uncoupled endothelial nitric oxide synthase (eNOS) and 
reduced expression of vascular thrombomodulin in their aorta [108, 110]. The hypertensive and 
prothrombotic state in PRCP gene trapped mice was abrogated by antioxidant treatment using 
mitoTEMPO, apocynin, and Tempol [107]. The paper demonstrates that the hypertensive and 
prothrombotic state arose from high levels of ROS in PRCP gene trapped mice, and this state 
was reversed by antioxidant treatment. The potential of antioxidants treatment in cigarette 
smokers to suppress smoking related cardiovascular disease is worth exploring.  
Shifting from urinary thrombomodulin, we are also interested in plasma thrombomodulin. 
The level of plasma thrombomodulin has been associated as an indicator of endothelial damage 
in patients with disseminated intravascular coagulation syndrome, pulmonary thromboembolism, 
adult respiratory distress syndrome, chronic renal failure, acute hepatic failure, atherosclerosis 
[121, 215-217]. In one study, plasma thrombomodulin concentrations of smokers and non 
smokers were studied [218]. They found the plasma levels of cigarette smokers was 15% lower 
than the mean. We would like to see if there is any correlation between the concentration of 
plasma thrombomodulin and methionine 388 oxidation in cigarette smokers.   
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Conclusion  
We have shown that methionine 388 is significantly more oxidized in smokers than non-
smokers.  Oxidative damage to the endothelium from the oxidants in cigarette smoke has been 
suggested to be an important factor for the development of cardiovascular diseases in smokers. 
Smokers are in a hypercoagulable state, but this is the first evidence for a specific molecular 
origin of this state. Methionine 388 oxidation has been shown in vitro to have large effects on the 
activity of the thrombomodulin. The mutation of thrombomodulin methionine 388 to any other 
residues, except leucine, decreases the anticoagulant cofactor activity of thrombomodulin [91].  
More importantly, there is 76-90% loss of activity when Met388 is oxidized [92]. We believe 
oxidation methionine 388 of thrombomodulin is one of the key molecular causes of the 
prothrombotic state in smokers and thus a critical factor in the development of thrombosis and 
premature death in smokers. In this chapter we have shown a method allows the semi 
quantitative analysis of methionine 388 oxidation in the thrombomodulin isolated from urine 
sample. This method offers a useful way to compare thrombomodulin oxidation in cigarette 
smokers and non smokers.  In this study we report that methionine 388 of thrombomodulin is 
more oxidized in cigarette smokers than in non smokers, and we propose that one of the 
molecular causes for prethrombotic state seen in smokers is from oxidation of methionine 388 of 
thrombomodulin.    
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